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ABSTRACT 
Background 
Venous thromboembolism is a serious disease comprising both pulmonary embolism and 
deep vein thrombosis. Venous thromboembolism causes considerable mortality and 
morbidity, with residual symptoms such as pulmonary hypertension and post thrombotic 
syndrome. Current assays for venous thromboembolism and the predisposition to develop 
venous thromboembolisms (thrombophilia) can only reflect a fragment of the complicated 
hemostatic processes. This thesis evaluates the usefulness of current and emerging 
hemostatic assays that reflect several aspects of the hemostatic process. Increased 
diagnostic specificity would enable better diagnosis and risk stratification of patients with 
venous thromboembolism. Improved biomarkers for venous thromboembolism and 
thrombophilia have the potential to prevent major morbidity and mortality by guiding 
treatment and prophylaxis to the right patients at the right time. 
Aim 
The aim of this project was to investigate assays that could improve the care for patients 
with suspected venous thromboembolism or thrombophilia. We evaluated the usefulness of 
current and emerging biomarkers for venous thromboembolism, explored the utility of 
emerging biomarkers for thrombophilia and functionally characterized a novel 
prothrombotic genetic variant. 
Methods 
A prospective case-control study of 954 patients with clinically suspected acute deep 
venous thrombosis or pulmonary embolism were recruited from the emergency department 
and analyzed by four D-dimer assays, fibrin monomers, thrombin generation and fibrin 
aggregation assays. The discriminatory accuracy of all assays and of age-adjusted cutoffs 
for D-dimer was evaluated. 
From the special coagulation laboratory, we included 369 patients with clinical criteria for 
thrombophilia testing. Plasma and DNA samples were analyzed by the global hemostatic 
assays Overall Hemostatic Potential (OHP) and Endogenous Thrombin Potential (ETP) as 
well as genotyped for several prothrombotic variants.  
In a separate study, a novel genetic variant with possible prothrombotic effect was 
characterized by the same assays, prothrombin levels, mRNA expression, and scanning 
electron microscopy of fibrin clot structure. 
 
  
 
Conclusion 
Use of age-adjusted cutoffs for D-dimer could lead to a >5% decrease in false positivity 
rate and in elderly patients this avoidance of unwarranted radiology could even affect as 
many as 20% of patients with suspected venous thromboembolism. The Overall Hemostatic 
Potential, Endogenous Thrombin Potential and fibrin monomer assay were not superior to 
D-dimer for diagnosis of deep venous thrombosis or pulmonary embolism. Global 
hemostatic assays and extended investigation of prothrombotic genetic variants discretely 
improved the predictive ability of the classical genetic thrombophilia markers and the 
proportion of patients with verifiable hypercoagulability. We could also suggest a 
connection between increased thrombotic risk  and a recently discovered synonymous 
single nucleotide polymorphism.   
  
 
SVENSK INTRODUKTION 
Venösa blodproppar drabbar mer än 20 000 personer årligen i Sverige, varav 25% av 
patienterna får kvarstående besvär. Vanligen drabbas benets djupa vener eller venerna i 
lungan, med bensvullnad respektive andnöd som huvudsymtom. Blodpropp i lungan är en 
akut och allvarlig, i vissa fall även livshotande sjukdom. Blodproppar kan bero på yttre 
orsaker som benbrott eller graviditet. De kan också bero på skillnader i blodets 
sammansättning, som gör att vissa har lättare att få blodpropp än andra.  
Läkare som misstänker venösa blodproppar har få användbara biomarkörer till sin hjälp, 
främst mäts D-dimer i blodprov. Tyvärr erhålls opålitliga provsvar om patienten har vissa 
andra sjukdomar eller andra tillstånd samtidigt. Exempelvis störs analysen av infektioner, 
inflammation, cancer och normala tillstånd som graviditet och stigande ålder. På 
akutmottagningen tvingas man därför ofta till att utreda misstänkta venösa blodproppar med 
speciella röntgenundersökningar med långa väntetider och viss risk för patientskada ifrån 
strålning och kontrastmedel.  
Att bedöma risknivån för att få framtida venösa blodproppar är också ett område där det 
saknas optimala biomarkörer. Om riskbedömningen skulle kunna stöttas genom bättre 
markörer för propprisk, så skulle det öka sannolikheten för att rätt patienter skulle ordineras 
blodförtunnande mediciner.  Förhoppningsvis skulle detta kunna minska både onödiga 
blödningsrisker och risken för allvarliga proppar. 
Denna avhandling har undersökt sätt att förbättra biomarkörer för diagnos av blodpropp och 
blodproppsrisk. Vi har gjort det genom att utvärdera utvecklingar av dagens biomarkörer 
och även lovande nya markörer. Vi har också undersökt en nyligen upptäckt mutation, som 
tycks vara kopplad till ökad propprisk, för att klargöra dess verkningsmekanism.  
I den här avhandlingen har vi samarbetat mellan olika kliniker och sjukhus, samt med 
diagnostikaindustri och forskningslaboratorier i Sverige och Europa. I utvärderingen har vi 
utnyttjat den stora mängd blodprover som passerat Stockholms sjukhuslaboratorier och 
använt överblivet provmaterial som annars skulle ha kasserats. Trots att vi haft varierande 
framgång med att hitta bra biomarkörer, är min förhoppning att våra framsteg ska bidra till 
att förbättra människors hälsa i närtid och på sikt. 
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1 BACKGROUND  
1.1 VENOUS THROMBOEMBOLISM  
1.1.1 Morbidity and mortality 
Venous thromboembolism (VTE) is the third most common cardiovascular disease 1 and a 
cause of substantial morbidity and mortality worldwide. VTE is estimated to be the leading 
cause of preventable hospital mortality 2 and causes a considerable health economic cost 3. 
However, even though verified VTE is treatable and most prophylactic treatment options 
are well-tolerated 4, both VTE and thrombophilia are under-diagnosed and under-treated 5-7. 
The problem could be reduced by treatment and selective prophylaxis in adequate time 4, 8. 
 
VTE is constituted primarily by deep 
venous thrombosis (DVT, 2/3) and 
pulmonary embolism (PE, 1/3) 5, Figure 1. 
More uncommon sites are portal vein 
thrombosis, upper extremity deep vein 
thrombosis, mesenteric vein thrombosis, 
renal vein thrombosis and cerebral venous 
sinus thrombosis.  
VTE occurs in 2-3/1000 individuals, with 
an incidence in adolescence of 0.1/1000, 
increasing to 8/1000 above 80 years of age 
9. Women are subject to VTEs earlier in life 
than men, explained by the fact that they 
are provoked by hormone-based 
contraceptives and pregnancy 7, 10, but there 
is no difference in overall incidence 
between men and women. Men have a 75% 
higher risk of a recurrent VTE after a first 
episode 11 and the age-related increase in 
VTE  begins by the age of 50 in men and 
60 in women 7.   
Figure 1. DVT in leg embolizing to the lungs   
and becoming a pulmonary embolism.  
Image: David Gifford, Science photo library 
 
 2 
 
 
The most frequent symptoms at diagnosis of DVT are pain (82.8 %) and swelling of 
extremities (73.3 %). The corresponding symptoms of PE are dyspnea (75.6 %) and chest 
pain (45.5 %) 1. Aside from acute symptoms, VTE causes considerable long-term morbidity 
with 25% of patients developing residual symptoms such as post-thrombotic syndrome with 
ulcerations and chronic swollenness and chronic pulmonary hypertension 3. VTE is 
considered a chronic disease, because of the highly prevalent residual symptoms and the 
permanent increased risk of recurrent venous thrombosis 5, with a cumulative recurrence 
rate after ten years of about 30% 12. VTE is also the major cause of lost disability-adjusted 
life years (DALYs) in both high and low-income countries 13. 
In addition to the considerable morbidity of VTE, the thirty-day all-cause mortality of 
pulmonary embolism is approximately 12% and DVT 6% 10. An estimated 12% of all 
deaths in Europe are caused by PE 5. Fatal PEs are only diagnosed previous to death in 7% 
of cases, the majority of fatal events are PE that have remained undiagnosed and sudden 
fatal PE, with 59% and 34% respectively 5. The morbidity and mortality of VTE could be 
significantly reduced by prevention, early correct diagnosis and appropriate treatment 4, 8.  
1.1.2 Classification of deep venous thrombosis and pulmonary embolism 
PE is divided into segmental PE and subsegmental PE (ssPE), determined by imaging 
techniques. DVT the leg is classified as distal or proximal; where distal DVT is located 
below the popliteal vein. The subset of distal DVTs that are isolated to the muscular veins 
of the calf, and do not extend into the deep venous system (i.e. soleus, gastrocnemius) are 
classified as muscle vein thromboses. Distal DVT if left untreated, can be expected to 
eventually extend into a proximal DVT and possibly further into PE in about 15% of cases4.  
Symptoms of VTE are related to localization and size, distal DVT and ssPEs are to a higher 
extent without symptoms and/or critical clinical complications. Subsequently, whether or 
not to treat smaller VTEs is a challenging decision, given the bleeding risk of anticoagulant 
therapy. In Sweden, isolated distal DVTs are treated for four weeks to six months, primarily 
based on symptoms, VTE size and risk factors for recurrent VTE. However, many 
guidelines maintain that patients with small VTE may have a negative risk-benefit-ratio 
from anticoagulant treatment. The recent CHEST* guidelines for antithrombotic therapy for 
VTE recommend surveillance over treatment in distal DVT and ssPE, unless the patient has 
serious symptoms or risk factors 4.  
* CHEST; the official publication of the American College of Chest Physicians 
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1.2 PATHOGENESIS OF VENOUS THROMBOEMBOLISM 
 
Figure 2. Modern rendition of Virchow’s triad, adapted from Byrnes et al. 14. 
1.2.1 Virchow’s Triad  
Venous thrombosis has classically been described as a combined effect of prothrombotic 
changes in the blood flow, vascular wall and blood composition, i.e. Virchow’s Triad 15, 
Figure 2. The model is as relevant as ever. Blood composition would currently be 
considered to encompass the individual concentrations of pro- and anticoagulant proteins 
and hematologic cells as well as cell derived microvesicles. Reduced blood flow or stasis is 
still highly relevant in VTE, because venous clots are formed under low shear stress in 
contrast to arterial clots 16, 17. Reduced flow or static blood in the valve pocket sinuses 
decreases the inhibiting regulation that wall shear stress normally has on the endothelial 
lining of the blood vessel and leads to initiation of thrombus formation 18. The endothelial 
cells of the vessel walls have been demonstrated as important in formation of both venous 
and arterial thrombi. Although, in venous thrombosis formation, the endothelial lining is 
mainly intact, unlike in arterial thrombosis formation 17.  
Contemporary concepts that complement Virchow’s Triad, are the cell-based model of 
hemostasis, which describes how essential the activated platelets are for the plasma 
coagulation 19 and the intimate interactions of platelets and coagulation factors in VTE 20.  
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1.2.2 Endothelial Cells 
An important initiator of VTE formation is the activation of endothelial cells, primarily 
caused by the hypoxia that may arise in the valve pocket sinuses, or possibly by 
inflammation. Activation leads to expression of adhesion receptors to the cell surfaces, 
facilitating binding of circulating leukocytes and microvesicles. Subsequent activation of 
monocytes induces expression and de-encryption of tissue factor (TF) 21. TF is a potent 
procoagulant surface antigen, constitutively expressed on the cells that form an anti-
hemorrhagic envelope around blood vessels, especially in critical organs such as the brain, 
heart and lungs. Expression of TF can also be induced in activated endothelial cells and 
monocytes. TF is additionally present on monocyte derived microvesicles and possibly on 
neutrophils, eosinophils and T-cells and activated platelets with derived microvesicles, 
although this is controversial 21, Figure 3.   
Activated monocytes with increased expression of TF are most probably an important 
driving factor behind the increased risk for VTE in sepsis, cancer and after surgery 17, 21. 
1.2.3 Coagulation Cascade 
TF in complex with activate Factor VII (FVIIa) initiates coagulation and induces thrombus 
formation. The primary source of FVIIa needed for the initiation of coagulation is thought to 
be the minute amounts of free FVIIa present in the circulation. The complex of TF-FVIIa, 
the extrinsic tenase complex, activates small amounts of Factor X and Factor IX (which is 
the primary substrate of the complex). Activated Factor Xa (FXa), adsorbed on the cell 
surface, can convert some prothrombin into cell-bound meizothrombin, which can activate 
some Factor V (FV), released by activated platelets. Activated FV (FVa)  binds to FXa 
forming the prothrombinase complex, which activates small amounts of prothrombin into 
thrombin. The initiation phase of the coagulation is concluded when thrombin activates the 
cofactors Factor V and Factor VIII as well as Factor XI, Factor VII, Factor XIII and platelets.  
The prothrombinase complex and the intrinsic tenase complex, a complex of FVIIIa-FIXa, 
assemble on the negative surfaces of activated platelets. This increases their enzymatic 
efficiency manifold leading to the generation of large amounts of FXa and thrombin 22. The 
propagation of the coagulation cascade is additionally driven by the activation of FIX by 
FXIa, generated in the initiation phase. Thrombin also initially feed-back stimulates its own 
generation by activating more FVII, although the TF-FVIIa-complex is quickly inhibited by 
Tissue Factor Pathway Inhibitor (TFPI) after the initiation of coagulation 21. 
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Factor XIIa (FXIIa) is another driver of thrombus formation and is considered by some to 
play a part in the formation of pathological VTE associated with immunothrombosis and 
cancer. After activation by negative surfaces, such as extracellular nucleic acids or 
polyphosphates from activated platelets or bacteria 23, FXIIa activates Factor XI and 
thereby the intrinsic path of the coagulation cascade, see Figure 3. 
 
Figure 3. Pathological activation of the extrinsic pathway via Tissue Factor (TF) 
expression in activated monocytes, cell derived micro vesicles (MV) and activated 
endothelial cells. Cellular RNA and polyphosphate (PolyP) released from activated 
platelets or bacteria activate FXIIa in the intrinsic pathway. Mackman 17. 
1.2.4 Platelets 
It is now clear that activated platelets have a role not only in the primary, but also in the 
secondary hemostasis, primarily because they provide the negative cell surfaces where the 
coagulation process is localized, which both enhances the thrombin generation, protects the 
coagulation enzymes from inhibition and regulates that coagulation is not disseminated in 
the circulation. Platelets are activated by the exposure of subendothelial collagen in 
hemostasis, but can also be activated by thrombin via activation of protease-activated 
receptors on the platelet cell membrane, a pathway that is active in both hemostasis and 
VTE formation 20. Activated platelets also contribute activating factors to many steps of the 
coagulation process. Upon activation and degranulation, the content of the α-granules is 
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released, which contains a large amount of different proteins, some of which are 
coagulation factors; fibrinogen (endocytosed from blood), platelet FV, FXIII, Ca2+ (i.e. 
Coagulation Factor IV), von Willebrand factor as well as FVIII, FIX and FXI according to 
some reports 22. Procoagulant platelet polyphosphates are also released at the degranulation 
of the dense granulae of the platelets. The mechanism for their procoagulant activity is still 
controversial, but they have been claimed to directly activate FXII 24-26. As mentioned 
before it is also controversial whether activated platelets and platelet derived microvesicles 
are a source of intravascular, cell membrane bound TF 21. 
1.2.5 Fibrinogen and fibrin degradation products  
Thrombin is the key enzyme in the coagulation because it is a platelet agonist, activates 
several coagulation factors, FV, FVII, FVIII, FXI and FXIII, and not least because it 
converts fibrinogen into fibrin in the final step of the coagulation cascade. The fibrin 
monomers (FM) then self-polymerize into insoluble fibrils. The fibrils are cross-linked into 
fibrin networks by the transglutaminase Factor XIIIa.  
The structure of the fibrin clot 
will determine the resistance to 
fibrinolysis 27; tight fibrin 
structures with thin fibers, 
increased number of branch 
points and small pores result in a 
slower fibrinolysis rate than a 
loose structure of thick and 
unbranched fibers. Clot structure 
is affected by thrombin 
concentration, and to a lesser 
extent by pH, ionic strength, 
Ca2+, fibrinogen concentration 
and FXIII 28. In fibrinolysis, 
degradation products are released 
into plasma, some carrying the 
epitope of two adjacent               
D moieties of cross-linked fibrin, 
known as D-dimers.  
Figure 4. Blood clot visualized by SEM.                 
Red; erythrocytes, white; fibrin, pink; platelets. 
Image: Susumu Nishinaga, Science photo library. 
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1.3 DIAGNOSIS OF VENOUS THROMBOEMBOLISM  
1.3.1 Clinical prediction rules for venous thromboembolism 
DVT and PE can present with very discrete symptoms, or with symptoms similar to other 
conditions. A definite diagnosis of DVT and/or PE can generally not be achieved by only 
clinical examination of the patient, and the quality of laboratory assays and imaging 
techniques are of utmost importance. Diagnosis of VTE is based on a sequential approach 
following a clinical pre-test probability assessment (Figure 5). In patients with low pre-test 
probability for VTE, D-dimer is analyzed in plasma to potentially exclude VTE, if negative. 
Mid/high pre-test probability leads to imaging that can verify or rule out DVT or PE 29. 
Clinical pre-test probability assessment is most often done by the Wells clinical prediction 
rule for DVT and by the Wells rule for PE 29 or the Geneva rule. The Wells and Geneva 
rules for PE have similar accuracy, based on a systematic meta-analysis 30 and a direct 
prospective comparison 31. 
Figure 5. Diagnostic algorithm for DVT and Pulmonary Embolism in the emergency department, 
Socialstyrelsen 32. 
1.3.2 Diagnosis of deep venous thrombosis in the leg 
DVT can be verified by venography of the lower extremity or whole-leg echo-color-
doppler ultrasonography. Venous 2-point compression ultrasonography (CUS), with 
compression at the inguinal and the popliteal vein can also be used to verify DVT. The 
Gold Standard is venography, which is however associated with exposure to radiation and 
intravenous contrast, both of which can have adverse iatrogenic effects 33, 34.  
Clinical 
assessment
Low clinical
probability
D-dimer
Negative         
D-dimer
Positive          
D-dimer
High clinical
probability
Imaging
Exclude VTE
Verify VTE
 8 
 
Many guidelines recommend the two-point CUS, the CHEST* guidelines even discourage 
the use of whole leg examination 4. There are practical and economical motives to these 
recommendations, based on the increased simplicity and repeatability of the 2-point CUS. 
The clinical importance of diagnosing distal DVT and muscle vein thrombosis is also 
highly debatable, as discussed in section 1.2.2. A meta-analysis of the accuracy of non-
invasive diagnosis of DVT calculated the weighted mean sensitivity of CUS to detect 
symptomatic proximal DVT to 94% [95% confidence interval (CI) 92–95%] with a 
specificity of 98% [95% CI 97-98%]. The sensitivity for detecting distal proximal DVTs 
was 91% [ 95% CI 82-96%] and the specificity 99% [95% CI 97-100%] 35. CUS has also 
been shown in one randomized controlled trial (RCT) to be clinically equivalent to whole 
leg ECD, when used for the management of symptomatic outpatients with suspected DVT  
of the lower extremities 36. This has been interpreted by many in the field as corroborating 
the theory that distal DVTs are clinically irrelevant, as distal DVTs can only be visualized 
by venography or Duplex-doppler ultrasonography 36.  
1.3.3 Verifying pulmonary embolism 
Computed tomography pulmonary angiography (CTPA) is the preferred technique for 
verifying PE, although it is associated with radiation and intravenous contrast medium with 
risk for adverse effects 33, 34. Patients that cannot be exposed to this risk, are referred to 
pulmonary ventilation-perfusion scintigraphy, however associated with the risk of 
intravenous isotopes 35.  
Since the introduction of CTPA for diagnosing PE, the frequency of ssPE has increased 
from approximately 5% to more than 10% of PEs 1. The apparent incidence of PE has also 
increased by 80% during the same period, without a significant decrease in mortality 
following the supposed increased proportion of patients that received anticoagulant 
treatment 37. This notable dissonance is another argument for the stance that ssPE are 
clinically irrelevant and should generally not receive anticoagulation.  
1.3.4 D-dimer as a biomarker of venous thromboembolism 
While imaging techniques are important to verify VTE, the use of biomarkers in selected 
cases has the advantage of reduced cost, time and iatrogenic complications. D-dimer in 
plasma reflects the recent activation of both hemostasis and fibrinolysis, because they are 
the degradation products of cross-linked polymerized fibrin. D-dimer assays are 
immunochemical, using antibodies directed against the epitope of two interconnected 
terminal D-subunits of fibrinogen, Figure 6.  
* CHEST; the official publication of the American College of Chest Physicians 
 9 
 
Figure 6. Formation and measurement of D-dimer, adapted from Lippi et al 38. 
Initially, D-dimer was analyzed by ELISA methods, but high-throughput nephelometry or 
particle-enhanced turbidimetry are now standard. The quantitative results cannot easily be 
related between assays. The poor analytical comparability is due to size heterogeneity of 
the D-Dimer fragments, and that assays have different reactivity for the various fragment 
lengths 39, 40. There is presently no international reference calibrator for D-dimer because 
the balance of different fragment sizes varies inter-individually as well as with clinical 
conditions 41. Conditions with an interrupted blood flow, such as thromboembolism, tend to 
produce shorter fragments whereas conditions with a maintained flow such as disseminated 
intravascular coagulation (DIC) generally produces longer fragments 39. To improve the 
comparability of D-dimer, results are preferably reported in mg/L Fibrinogen Equivalent 
Units (FEU) or mg/L D-dimer Equivalent Units (D-DU) 38.  
D-dimer assays generally have a high diagnostic sensitivity for VTE, but specificity for 
VTE is low due to other causes of fibrin strand formation. D-dimer is formed in several 
other conditions than fibrin aggregation in thrombosis42, such as pregnancy, cancer, trauma, 
inflammation, infection and advanced age 43. Many of these conditions are associated with 
an increased risk of venous thrombosis and they are frequently encountered in VTE-
patients. The clinical implications are extensive, particularly in patients with comorbidities 
or advanced age. Despite the low specificity, D-dimer is the only biomarker in common 
clinical use for diagnosis of VTE 38.  
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Since false positive results are so common, D-dimer has been determined to be clinically 
valuable only in cases with low pre-test probability. The recommendation is to exclusively 
use D-dimer to rule out PE and DVT of the lower extremities in patients with a low clinical 
probability 29, 38. To optimize this functionality, D-dimer cutoffs are set at a level where 
sensitivity is maximal. The Clinical and Laboratory Standards Institute (CLSI) recommends 
that cutoff be set so that sensitivity is ≥ 97%, with lower limit of 95% confidence interval 
[95% CI] of ≥ 90% and negative predictive value (NPV) ≥ 98% with lower limit of 95% CI 
of ≥ 95%). The recommendation regards D-dimer analysis to rule out VTE in a clinical 
population with low or intermediate pretest probability of VTE 44. It is not defined whether 
the high sensitivity includes exclusion of distal DVT and ssPE, which are associated with 
lower D-dimer concentrations and a higher degree of false negative results 45. 
Both the prevalence of VTE and the plasma concentration of D-dimer increase with age. 
Even in a healthy population of ≥70-year old’s, 50% have a D-dimer concentration above 
the cut-off 46. Some advocate that D-dimer testing should be entirely avoided in the elderly 
46, 47, but the effect of this approach would be that patients had to undergo imaging 
techniques instead, even when the probability of VTE was low. Age-adjusted cutoffs have 
been validated and recommended in DVT and PE, to increase specificity and markedly 
decrease the rate of false positive results in older patients while preserving sensitivity 48-52. 
Some clinical guidelines already recommend the use of age-adjusted cut-off values 37, 53, 54, 
using the formula originally suggested by Douma et al. in 2010 55. However the opinion has 
been questioned 56-58, and a recent Cochrane review of D-Dimer to rule out pulmonary 
embolism did not find enough evidence to recommend age-adjusted cutoffs 59. 
1.3.5 Fibrin monomers and additional biomarkers of venous thromboembolism 
Another marker of activated coagulation which can be of use in acute thrombosis is fibrin 
that has not yet polymerized, as measured in the assays Fibrin Monomers (FM) and Soluble 
Fibrin 60, 61. The latter is comprised of different lengths of still soluble oligomerized fibrin, 
whereas FM is a more homogenous measurand. Both assays are immunochemical analyses 
by ELISA or particle enhanced turbidimetry.  
Concentrations are demonstrably low in normal plasma, and increase faster than D-dimer in 
thrombotic disease 62. However, it is important to bear in mind that anticoagulant therapy 
rapidly normalizes the amount of circulating FM 63. Soluble fibrin and FM could be 
alternatives to D-dimer to determine acute VTE, if the diagnostic sensitivity was also 
sufficient. FM or soluble fibrin could therwisepossibly improve diagnosis if used together 
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with D-dimer for the exclusion of VTE 64. To date, the high variability between assays has 
been part of retarding the broad clinical implementation of these assays. Possibly, an 
alternative would be to analyze FM together with D-Dimer to counteract the lower 
sensitivity of FM 63.  
Another marker of venous thrombosis, but also of ongoing thrombin generation in vivo, is 
the prothrombin fragment 1+2 (F1+2) analyzed in plasma or urine. F1+2 is a fragment of 
the prothrombin molecule with a half-life of approximately 90 minutes, that is discharged 
when prothrombin is cleaved into thrombin by the prothrombinase complex. F1+2 has been 
utilized to assess thrombotic risk and monitor anticoagulant therapy but is also elevated in 
acute VTE and in the same common conditions that increase the D-dimer. In comparisons 
with D-dimer, F1+2 has displayed less diagnostic sensitivity and inferior diagnostic ability 
by receiver operating characteristic (ROC) 65. Another thrombin related marker that has 
gone out of vogue is the thrombin-antithrombin complex, which could also be used as a less 
sensitive than D-dimer marker of acute VTE. The complex is formed when the coagulation 
cascade is inhibited as thrombin cleaves antithrombin and forms a covalent 1:1 thrombin-
antithrombin complex, that is rapidly cleared from circulation, with a half-life of 15 min 65. 
Both F1+2 and the thrombin-antithrombin complex are now primarily biomarkers of in vivo 
thrombin generation and neither was established as a clinical routine marker.  
Several other biomarkers have been investigated for the diagnosis of acute VTE, for 
example CRP, neutrophil-lymphocyte ratio 66, mean platelet volume 66, p-selectin 67, 
Protein S, APC-PC inhibitor complex, coagulation Factor VIII, von Willebrand factor, 
platelet derived TF-bearing microvesicles 68 and markers of neutrophil extracellular traps 69.  
1.3.6 Clinical risk factors for venous thromboembolism 
Patients with increased risk for a first or recurrent VTE event may be indefinitely treated 
with prophylactic anticoagulants. Individual risk prediction is challenging and risks of both 
recurrent thrombosis and bleeding differ substantially between individuals. The effects of 
anticoagulant prophylaxis compared to placebo in patients with high-risk of VTE has been 
evaluated in several meta-analyses. The data on bleeding risks have been inconsistent, but 
because both risks continue indefinitely, the cumulative probability of either a bleeding or a 
thrombotic event is high The collective conclusion is that prophylaxis is effective for 
preventing VTE and individual assessments must determine if patients have sufficient risk 
to justify the risk-benefit trade-off 8.   
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Strong risk factors (OR >10) Moderate risk factors (OR 2–9) 
Fracture of leg Arthroscopic knee surgery 
Hip or knee replacement Autoimmune diseases 
Hospitalization for chronic heart failure Blood transfusion 
Myocardial infarction (3 months) Central venous lines 
Major trauma Intravenous catheters and leads 
Spinal cord injury Chemotherapy 
Prior VTE Congestive heart failure or respiratory failure 
Weak risk factors (OR <2)  Erythropoiesis-stimulating agents 
Bed rest >3 days Hormone replacement therapy (formulation) 
Diabetes mellitus In vitro fertilization 
Arterial hypertension Oral contraceptive therapy 
Immobility due to sitting (e.g. air travel) Post-partum period 
Increasing age Infection (specifically pneumonia, UTI, HIV) 
Laparoscopic surgery Inflammatory bowel disease 
Obesity Cancer (highest risk in metastatic disease) 
Pregnancy Paralytic stroke 
Table 1. Transient and persistent risk factors predisposing for venous thromboembolism, 
adapted from 2019 ESC Guidelines for pulmonary embolism 37. 
Evaluation of known and possible risk factors for VTE is crucial in order to weigh bleeding 
risk against risk for first and recurrent VTE. Risk factors for VTE are classified as acquired 
or inherent and are also divided into transient or persistent risk factors. VTE that is 
ostensibly unprovoked, has historically been labelled as idiopathic VTE and can constitute 
as many as 25% of events 70. These patients are presumably burdened with one or more 
persistent, inherent risk factor. Clinical risk factors other than thrombophilia are 
demonstrated in Table 1 37. 
1.3.7 Thrombophilia investigation 
Most permanent risk factors for VTE are known to the patient, but patients with idiopathic 
VTE may have a previously undiagnosed thrombophilia. Thrombophilia is a term for 
inherited or acquired hemostatic disorders with an increased coagulation tendency and with 
a risk of thrombotic conditions. It is associated with a moderately increased risk for VTE 71, 
72 and some obstetric complications 73, 74. Testing for thrombophilia has the potential to 
limit first-time VTE by indicating increased need for prophylaxis with anticoagulants, and 
possibly also recurrent VTE by secondary prophylaxis. The routine inherited thrombophilia 
panel consists of the Factor V Leiden mutation (FVL), the Prothrombin G20210A mutation 
(FII c.20210G>A ), deficiencies of antithrombin, protein C and protein S, lupus 
anticoagulant and antiphospholipid antibodies.   
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The clinical indications for performing thrombophilia testing are a matter of debate because 
broad testing in various conditions has become increasingly common. Often with little 
guiding effect on treatment decisions. There are also potential negative effects of testing for 
thrombophilia, such as anxiety in the tested subjects, that the testing panel is expensive and 
that patients with a mild increase in the risk for VTE can encounter insurance 
discrimination 75. A Cochrane review on thrombophilia testing for prevention of recurrent 
venous thrombosis concluded that it is unknown whether thrombophilia testing can actually 
reduce recurrence of VTE after a first episode, because there have been no prospective 
controlled clinical trials with thrombophilia testing as the intervention and recurrent VTE as 
the outcome measure 76. There are however numerous retrospective studies on 
thrombophilia outcome, e.g. one large case-control study that concluded that recurrence of 
VTE was not reduced by testing for inherited thrombophilia in a retrospective setting 77. 
There are also prospective cohort studies showing that unselected testing for heritable 
thrombophilia does not decrease recurrence of thrombosis 78. The conclusion of the 
Cochrane review was that the assessment of whether a person should be tested or not 
should be completely individualized and depend on how plausible it is that testing would 
lead to risk reduction. Many clinical guidelines have adopted a similar approach, with 
recommendations of testing in limited groups of patients, primarily after early unprovoked 
VTE and in patients who would otherwise not receive prophylaxis 75.  
1.4 POTENTIAL BIOMARKERS FOR VTE AND THROMBOPHILIA 
Clinical biomarkers for a hypercoagulable state are limited to a panel of specific factors for 
thrombophilia and D-dimer for acute thrombosis. We need biomarkers with better 
specificity for acute thrombosis and increased clinical value for thrombophilia.  
1.4.1 Genetical biomarkers of thrombophilia 
A group of biomarkers that are already being used to some extent in the investigation of 
thrombophilia are the prothrombotic genetic variants, primarily single nucleotide 
polymorphisms (SNPs). Patients often report family histories of VTE 79 and the heritability 
of the disease is estimated at around 50 % in family studies 80 and 35% in GWAS. 
However, only ~5% can be explained by the common prothrombotic variants 81.  
To date  there are more than 88 known prothrombotic variants 82. The first described 
genetic thrombophilia was antithrombin deficiency, described by Egeberg in 1965 83. 
Subsequently thrombophilias with strong phenotypes were discovered by hypothesis driven 
research and sanger sequencing 84. The field later accelerated with the introduction of 
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genome wide association studies (GWAS) for first 85, 86 and recurrent VTE 87, and more 
recently, massive parallel sequencing 88, 89. But despite the numerous new thrombophilia 
variants, the panel for inherited thrombophilia has remained unchanged since 1996, when 
prothrombin c.20210G>A was added 90 and the clinical value of expanded genetic panels 
have not been thoroughly investigated.  
Amidst the controversy of thrombophilia testing, researchers of inherited thrombophilia are 
moving in two diametrically opposed directions. On the one hand, advocates of increased 
genetic thrombophilia testing see unlimited possibilities in evolution toward personalized 
medicine and possibly even massive parallel sequencing for risk stratification of venous 
thrombosis 91. On the other hand, international bodies with perspectives that are more 
connected to health economy, promote a more prudent view of limiting testing to a select 
few individuals. No clinical guideline has yet recommended analysis of any of the 
emerging SNPs 92. De Haan et al. 93 made an insert in the debate regarding which genetic 
variants would be of use in the clinical risk prediction of VTE, when they concluded that no 
additional value was added to heritable thrombophilia investigation beyond analysis of the 
five SNPs with the highest odds ratio (OR) for first time VTE. The study sequentially 
added 31 risk variants with decreasing ORs and evaluated diagnostic ability by ROC 
analysis, where the area under the ROC-curve (ROC AUC) increased from 0.77 for only 
Figure 7. Odds ratios for first venous thrombosis were calculated relative to the median 
number of risk alleles among control subjects, de Haan et al 93.  
clinical risk factors to 0.82 for analysis of five SNPs, with knowledge of clinical risk 
factors. SNPs were added in order of the OR as found in the literature, starting with FVL in 
the score based on only one SNP, and then adding F2, ABO, FGG and F11 in the order 
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presented below, and so on. OR for first-time VTE ranged from <1-1 for 0-2 risk alleles up 
to OR 7.48 (95 % CI, 4.49 - 12.46) for ≥ 6 risk alleles, Figure 7.   
1. Factor V Leiden c.1691G>A (rs6025) inhibits the proteolytic inactivation of Factor V 
by active protein C (APC), i.e. APC-resistance 94. It also impairs the slow activation of 
Factor V to the ACP-cofactor Factor V anticoagulant, resulting in inefficient FVIIIa 
inactivation 95. The SNP is common in caucasians, where the prevalence is 2-10% 95. The 
literature average OR for VTE is 3.79 in heterozygotes 93.  
2. Prothrombin, FII c.20210G>A (rs1799963) located at the 3’ end of the F2 gene 96 is 
associated with increased but very variable prothrombin activity levels 97 The variant is 
present only in caucasians, with a frequency of ~2% 90. 
3. Non-O blood group (rs8176719) is the most common genetic risk factor for VTE, with 
an OR of 1.85 93. The thrombotic risk is especially increased for pregnancy-related VTE 
and in women under treatment with combined oral contraceptive 98. The thrombotic 
mechanism is related to the blood group structures A, B, and H(O) in the oligosaccharides 
of von Willebrand factor (vWF). The extensive glycosylation of vWF in blood group A and 
B leads to longer half-life and higher concentrations of vWF and Factor VIII in plasma 99. 
In addition, ABO status has a synergistic role with other thrombophilia genetic risk factors 
such as Factor V Leiden and the FII c.20210G>A mutation 100. 
4. Fibrinogen c.10034C>T mutation (rs2066865) leads to alternative splicing of the 
fibrinogen γ-chain, thereby reducing plasma fibrinogen γ’. Low levels of γ’ is associated 
with an increased risk of thrombosis, because fibrin containing γ’ binds thrombin more 
effectively (“Antithrombin 1”) 101. The SNP increases the risk of VTE in Caucasians where 
the prevalence is close to 25%, and the literature average OR for VTE is 1.56 93.  
5. Factor XI, c.56-282T>C (rs2036914) a variant in intron 2 of F11 is common but only a 
mild thrombophilia factor, with OR 1.32 93. The increased risk of VTE is most probably 
caused by increased plasma levels of Factor XI. The SNP remains associated with DVT 
after adjustment for FXI levels, but this may be because of a closer association with 
average intra-individual FXI levels than with one single sample. 102.  
Summation of risk alleles in the five SNPs were proposed for prediction of both first 93 and 
recurrent VTE 87, 103. Other genetic panels for hereditary thrombophilia have been proposed 
by other groups. Soria et al. defined a clinical genetic risk algorithm for VTE risk 
assessment called ThromboInCode® (TiC), comprising a genetic risk score (GRS) of 
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twelve prothrombotic variants combined with clinical risk factors of VTE. The scores 
predictive capability for VTE was compared with Factor V Leiden and FII c.20210G>A, 
and TiC showed a discrete increase in AUC (0.68 versus 0.58, p<0.001). The addition of 
the FXI and FGG variants from the de Haan study did not improve the risk assessment 
compared to analysis by only TiC 104. The variants in TiC are a combination of low-
frequency variants with high ORs for VTE and globally common variants with low ORs. 
The variants included in the TiC GRS are:  
1. Factor V Leiden, FV c.1691G>A mutation (rs6025) described above. 
2. FV Cambridge, FV c.1091G>C (rs118203905) gives mild APC-resistance 95. 
3. FV Hong-Kong, FV c.1090A>G (rs118203906) the A allele is associated with mild 
APC-resistance, although not unequivocally 95. 
4. Prothrombin, FII c.20210G>A (rs1799963) described above. 
5-8. ABO haplotype A1, ABO (rs8176719, rs7853989, rs8176743 and rs8176750) are 
variants in the ABO gene that predispose for haplotype A1. While group O is 
associated with the lowest VTE-risk, A1 is associated with the highest risk and an 
incidence rate ratio of 1.88 – 2.61 98.  
9. Factor XII, FXII c.46C>T (rs1801020), a variant identified through a GWAS, giving 
increased plasma concentrations of Factor XII and susceptibility to thrombotic events 
105. Confirmed in case-control association studies as a risk factor for venous thrombosis 
and a thrombosis risk factor during first pregnancy. The OR of thromboembolic events 
is 5 times higher in homozygotic carriers than in non-carriers.  
10. Factor XIII, FXIII c.226G>T (rs5985), a variant with a protective effect against the 
risk of thromboembolism (39).The stabilization of the molecules of fibrin by the 
activated Factor XIII is an essential process for the formation of the clot and the V34L 
amino acid exchange in F XIII leads to changes in the fibrin clot structure (38).  
11. AT Cambridge II, SERPINC1 c.36232A>G (rs121909548) a variant causing 
antithrombin deficiency, type II with a decreased function in the heparin-binding 
domain. The variant is common and has classically been regarded as a very mild 
thrombotic risk factor 106, a stance which has been challenged 107. 
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12. Protein Z-dependent protease inhibitor, SERPINA10 c.7928C>T (rs2232698)     
The ZPI (Protein Z-dependent protease inhibitor) is a serpin inhibiting Factor Xa in the 
presence of protein Z, calcium and phospholipid and the Factor XIa without cofactor. 
Decreased levels of ZPI seem to be a mild risk factor for VTE, but some studies have 
reported a synergistic prothrombotic effect when combined with additional variants 
such as the FVL or FII c.20210G>A  108. The nonsense variant (R67X) in ZPI that is 
included in TiC is associated with decreased levels of ZPI 109, but has not decisively 
confirmed as a risk factor for VTE 110. 
A weakness of pre-assembled GRS is that the magnitude and direction of allelic effects can 
differ between populations. Epidemiological and genetic studies have also elucidated that 
there are significant ethnical differences regarding genetic etiology and incidence of VTE 
across populations that should also be addressed 111.Not all of the variants have been 
thoroughly evaluated, and based on current knowledge it is uncertain if they can be 
recommended for clinical thrombophilia testing 112.  
Prothrombotic variants in non-coding DNA regions are very rare 90 as are synonymous 
variants (synonymous single nucleotide polymorphism, sSNP). Synonymous variants have 
long been considered silent and phenotypically neutral, since they do not impact the amino 
acid sequence of the protein. But several studies during the last decade have demonstrated 
contribution of sSNPs to disease pathology through epigenetic changes 113 and a few 
prothrombotic sSNPs have been reported with change in protein expression as the main 
mechanism 114. Synonymous polymorphisms can in fact influence gene function in several 
ways including mRNA folding and stability 115. Increased knowledge of epigenetic 
mechanisms will hopefully enable a better understanding of sSNP disease mechanisms. 
Prothrombin Belgrade (FII c.1824C>T, rs3136532) is one such novel sSNP, which was 
described in a pilot study as a potential risk factor for recurrent pregnancy loss 116 and 
possibly VTE.  
1.4.2 Thrombin generation assays  
Other biomarkers that could be of use in both thrombophilia and acute VTE are the global 
hemostatic assay. In thrombophilia, the global hemostatic assays can potentially be used as 
screening tests. Conventional screening tests such as aPTT and PT (INR) are only useful in 
bleeding investigations, so routine thrombophilia screening is limited to analyzing a panel 
of specific risk factors. These factors can only explain up to 50% of unprovoked VTE 76, 
indicatin that other causes of hypercoagulability likely contribute to clinical idiopathic 
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VTE. A dependable screening test for the hypercoagulable state could revolutionize risk 
prediction, since an exhaustive exploration of every coagulation component would be both 
unfeasible and lack the global perspective on hemostasis. Global hemostatic assays may 
also be in better agreement with the hypercoagulable phenotype of patients. Still, the global 
hemostatic assays have had a hard time establishing their clinical value as screening tests. 
The global hemostatic assays are a class of assays that examine the combined effect of pro- 
and anticoagulant processes in plasma, because they register the complete coagulation 
process. Screening assays based on coagulation time, such as aPTT and PT (INR) are halted 
when only 3–5% of the total thrombin is formed 117, 118. The vast majority of the thrombin 
production with subsequent coagulation reactions, can therefore not be observed. Hemker et 
al. 119 introduced the first global hemostatic assay in 1993, when they continuously 
measured the generation of thrombin in plasma for a prolonged time. The assay was 
developed into the Calibrated Automated Thrombogram (CAT), Thrombinoscope 
(Maastricht, the Netherlands).  
Thrombin generation assays (TGA) have since shown elevated thrombin generation in 
intermediate and serious thrombophilic phenotypes 120, 121. Elevated thrombin generation 
has also been associated with an increased risk of VTE in several studies 122-124 and 
unprovoked recurrent VTE in some studies 125, however not in all studies 126. Some studies 
have demonstrated that thrombin generation measured in the presence of thrombomodulin 
allows for better appreciation of risk of recurrent VTE compared to measurement 
performed in the absence of thrombomodulin 127.  
A few studies have evaluated the use of TGA as a complement to D-dimer in the exclusion 
of venous thromboembolism 128, 129, these show promising results of increased specificity 
combined with solid sensitivity. Theoretically, the use of TGA in acute settings may 
however be prone to acute phase effects which have not been extensively evaluated yet. 
Of note is that the TGA still have poor interlaboratory reproducibility, due in part to non-
standardized calibrators, origin of TF and phospholipids, differences in substrates, and 
equipment 130, 131 and sensitivity to preanalytical conditions 132. External quality control 
programs are available and different standardization efforts have been made 133. Platelet 
poor plasma is recommended over platelet rich plasma in automated assays, because it 
requires addition of tissue factor (TF) and phospholipids in defined concentrations, which 
facilitates standardization 132. Normalization of results by external reference plasma has 
also been proposed 131, 134. In assays with low concentrations of triggering TF (≤ 1pM), corn 
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trypsin inhibitor is needed to reduce random effects of contact activation 132, 133, 135. 
However, the need to add corn trypsin inhibitor is somewhat controversial, mainly because 
of cost and because addition before blood sampling may be impractical. Despite 
standardization efforts reproducibility is a prevailing issue 133, 134.  
There are several automated and semi-automated assays 133, measuring thrombin generation 
continuously using fluorogenic or chromogenic thrombin substrates. The use of a 
chromogenic substrate necessitates use of platelet poor plasma without fibrin 119. The 
Innovance Endogenous Thrombin Potential (ETP) is a chromogenic TGA, automated on 
the BCS instrument from Siemens Healthcare (Erlangen, Germany) 136, 137. The ETP uses 
citrated platelet poor plasma with addition of recombinant TF in a high concentration, 
CaCl2, a non-defined fibrin aggregation inhibitor, a stabilizing buffer and the slow reacting 
chromogenic substrate H-β-Ala-Gly-Arg-paranitroaniline. Absorbance is continuously 
registered spectroscopically at 405 nm. The assay is calibrated using a proprietary 
calibration standard. The fact that the ETP is performed in platelet poor plasma and after 
the addition of a fibrin aggregation inhibitor is important for standardization, but also limits 
the global nature of the assay. High TF is also a key component to the reliable performance 
and acceptable variability in the ETP assay, but restricts thrombin generation to the 
extrinsic coagulation 137.  
 
Figure 8. Thrombogram of the Innovance ETP assay (BCS instrument) with parameters in red and 
the CAT assay with parameters in light blue. Illustrated reaction curve outlining the major 
thrombin generation parameters, Kintigh et al.130. 
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The thrombin generation parameters are calculated from the thrombin generation curve: the 
endogenous thrombin potential [ETP AUC], which is area under the curve, peak thrombin 
concentration [CMax], time required to reach Cmax [TMax] and the time to start of thrombin 
generation [TLag], Figure 8 and Table 4. 
The ETP parameter has been systematically validated as a hemostatic screening assay, 
reflecting both risk of thrombosis and bleeding. Specific thrombophilias have been shown 
to increase the ETP, with deficiency of protein S and protein C or factor V Leiden leading 
to an increased ETP of about 10% 120, 138, 139. ETP can also be used to monitor bleeding 
tendency, and an ETP below 20% of normal predicts an increased risk of bleeding 28.   
An issue that impacts the accuracy of the TGA is the existence of α-2-macroglobulin 
(α2M)-thrombin complexes in plasma. Thrombin inhibited by this unspecific antiprotease, 
is still able to cleave synthetic thrombin substrates < 8 kDa in thrombin generation assays, 
leading to a falsely elevated thrombin generation. The ETP mathematically corrects for the 
presence of α2M-trombin via calculations based on the assumption of normal α2M levels. 
However, concentrations differ significantly, related to age and conditions such as hepatitis 
C, pancreatitis or acute ischemic heart disease 130, introducing an interindividual variation 
in the physiological relevance of the TGA related to how extreme the α2M levels are. 
1.4.3 Overall Hemostasis Potential  
A theoretical drawback of the TGAs is that they do not measure the final step of the 
coagulation process, i.e. fibrin formation and susceptibility to fibrinolysis. However, the 
Overall Hemostasis Potential (OHP) provides additional information concerning the rate of 
fibrin aggregation and fibrinolysis. The OHP is a global hemostatic assay based on repeated 
turbidimetric determination of fibrin aggregation after the activation of clotting 140. The 
assay originally measured the coagulation phase but has been modified to also reflect the 
fibrinolytic phase with the addition of tissue-type plasminogen activator (tPA). This means 
it reflects the integrated effect of procoagulant, anticoagulant, and fibrinolytic factors. The 
fibrin aggregation and lysis time parameters can also be used to calculate a proxy to fibrin 
clot liquid permeability 141, 142. A similar turbidimetric global fibrin assay is the clot 
formation and lysis (CloFAL) assay 143. 
The OHP assay has not been widely studied in thrombosis but can potentially be used as a 
screening assay of both hypo- and hypercoagulable conditions 144-146. In smaller studies 
global fibrin generation assays have been shown to characterize the hypercoagulability after 
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a previous VTE 147, acute coronary syndrome 148, 149, acute stroke 150, antiphospholipid 
syndrome 151, diabetes 152, normal pregnancy 143, orthopedic trauma 153 and obstructive 
sleep apnea 154 as well as in various hypocoagulable states and anticoagulant treatment 155, 
156. In women with a history of pregnancy-provoked VTE, OHP showed hypercoagulability 
that could be attributed to increased fibrin generation and reduced fibrinolysis 157. 
Prolonged CLT have been associated with a mild increase in of first, but not recurrent DVT 
158, 159. Prolonged CLT has also been described in patients with acute ischemic or 
hemorrhagic stroke, along with decreased clot permeability and increased maximum clot 
turbidity 160. 
The assay uses a spectrophotometer (ELISA plate reader) to repeatedly register turbidity by 
absorbance at 405 nm, which reflects the amount of aggregated fibrin in the sample at each 
timepoint. In the short OHP protocol (2001), absorbance is measured every minute for 40 
min 161. The shorter protocol was optimized for use in clinical care and can sometimes be 
terminated before hypercoagulable samples have finished the reaction. In the longer 
protocol (2019), absorbance is measured every 12 seconds for 60 minutes. The longer 
protocol is less suited for acute settings but enables the calculation of parameters of clot 
formation and lysis times as a proxy for fibrin clot permeability 
Coagulation is activated by addition of CaCl2 and minute amounts of exogenous thrombin 
to platelet poor citrated plasma. In a second well on the microtiter plate, small amounts of 
tPA is also added to initiate fibrinolysis in parallel with coagulation. Two separate fibrin 
aggregation curves are therefore generated; the overall coagulation potential (OCP) and the 
overall hemostasis potential, OHP, Figure 9.  
The fibrinolytic system is assessed by the overall fibrinolysis potential (OFP); the 
difference between the OCP and OHP areas as well as the clot lysis time (CLT), i.e. the 
time from 50% of maximal clotting to 50% lysis 162. The parameters of the OHP and ETP 
are presented in Table 4. 
 
Figure 9. Graphical presentation of the fibrin aggregation curves and the OHP parameters 163, 
Figure used with the kind permission of Iva Pruner. 
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ETP AUC Area under the curve (%): Corresponds to the total amount 
of generated thrombin. 
 Cmax Peak height (%): Corresponds to the maximal simultaneous 
thrombin generation. 
 Tlag Lag time (sec): Time from the start of measurement until the 
initiation of thrombin generation. 
 Tmax Time to peak (sec): Time from the start of measurement until 
the time of maximal thrombin generation. 
OHP 
OCP 
Overall Coagulation Potential (abs sum): Area under the 
fibrin generation curve, without fibrinolysis. 
OHP 
Overall Hemostatic Potential: Area under the fibrin 
generation curve expressed by a summation of the 
absorbance values, with fibrinolysis (addition of tPA). 
OFP 
Overall Fibinolysis Potential (%): The difference between 
the OCP – OHP curves. Determined by the fibrinolytic 
system and the density and thickness of the fibres; thin 
fibres give a denser fibrin network and hence a slower 
degradation rate 164. 
Clot 
turbidity 
assay 
Lag time time point when exponential growth of the absorbance 
occurs 
Max abs the median absorbance value of three consecutive points 
where the curve reached a plateau less the lag turbidity 
Clotting rate the slope of line fitted from the point at the start of the 
exponential growth curve to the point reaching the plateau 
Max abs time the time to the plateau (without t-PA) or peak (with t-PA) 
Slope time the duration of the exponential growth curve 
 CLT clot lysis time; time from Max abs time and return to baseline 
Table 4. Parameters of the ETP and OHP, clot turbidity calculated from the  OHP. 
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1.4.4 Additional markers of hypercoagulability 
The aspects of coagulation which is reflected neither in the thrombin nor the fibrin 
generation assay, are the procoagulant and fibrinolytic activities related to blood flow 
characteristics and cellular elements. Namely because vascular components, hematologic 
cells and to varying extent also microvesicles are absent in plasma. Whole blood global 
hemostatic methods such as thromboelastography could potentially be one step closer to the 
in vivo coagulation, although these whole blood assays have very poor reproducibility and 
must be performed on fresh samples within a few hours of sampling 165.  
Another alternative, to capture at least one feature of the cellular aspect of hemostasis is 
measurement of cell derived microvesicles, which has the advantage of being possible in 
plasma. One additional aspect that is not reflected in any global hemostatic assay is the 
fibrin clot structure which can be assessed by liquid permeability, light scattering 
(turbidimetry), confocal microscopy and scanning electron microscopy. The visualization 
of fibrin clot networks allows for measurement of such variables as the fiber thickness and 
length, network density and porosity and the number of branch points.  
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2 AIMS 
The aim of this thesis was to improve laboratory diagnostics of venous thromboembolism 
and thrombophilia in close collaboration between research and clinical laboratories. 
The specific objectives of the studies were:  
Study I 
• Verify that age-adjusted D-dimer cut-offs for suspect acute venous thromboembolism 
(VTE) increased the specificity and reduced the rate of false-positive D-dimer results 
for older patients, without compromising the sensitivity 
• Compare four D-dimer assays common in Sweden, in order to facilitate the nation-
wide implementation of age-adjusted D-dimer cut-offs for VTE 
Study II 
• Compare the discriminatory accuracy of global plasma-based hemostatic assays, fibrin 
monomers and D-dimer, in the assessment of suspected acute VTE  
Study III 
• Assess the prevalence of hypercoagulable profiles in patients with a clinical indication 
for thrombophilia investigation, using plasma based global hemostatic assays 
• Assess the prevalence of hypercoagulable profiles in patients with conventionally 
verifiable thrombophilia  
Study IV 
• Investigate the frequency of the Factor II Belgrade variant in a Serbian population of 
patients with previous venous or arterial thromboembolism  
• Functionally characterize Factor II Belgrade to substantiate if the synonymous variant 
is associated with an increased thrombotic risk  
Study V 
• Validate the applicability of a Spanish genetic risk score (TiC) in Swedish patients  
• Evaluate the discriminatory accuracy of a new genetic risk score compared to current 
genetic analysis in patients investigated for thrombophilia 
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3 METHODS 
3.1 STUDY POPULATION AND STUDY DESIGN 
3.1.1 Acute Venous Thromboembolism (Study I and II) 
Study I and II formed a prospective case-control study investigating new approaches to 
laboratory diagnosis of suspect acute pulmonary embolism or deep venous thrombosis in a 
lower limb. Between April 2014 and May 2015, 954 consecutive out-patients were 
recruited from the emergency department of Karolinska University Hospital in Huddinge. 
The patients were included regardless of clinical probability of VTE and were sampled at 
the emergency department before initiation of any treatment. Study I evaluated age adjusted 
cutoffs in four D-dimer assays in 940 patients remaining after exclusions. Study II 
compared plasma-based global hemostatic assays to FM and D-dimer in a subset of 158 
patients, which corresponded to all available patients with VTE (n = 60) and patients 
without VTE as controls (n = 98), randomly selected after age- and sex-stratification 
(Figure 10). Clinical data was retrospectively collected from patients’ medical records, 
blinded for assay results.  
 
 
 
 
 
 
Figure 10. Flow chart of samples in study II. 
VTE was radiologically verified (n = 125) or, in patients without VTE, excluded 
radiologically (n = 391) or by a three month follow up of medical records (n = 424). 
Isolated thrombophlebitis was present in 9 cases and was classified as negative for VTE. 
Radiology was accredited according to ISO/IEC 17025 by the Swedish Board for 
Accreditation and Conformity Assessment and was performed on the day of sampling in 83 
patients, the following day in 15 patients, three days after sampling in three patients and 
after seven days in two patients. Radiology consisted of CTPA or ventilation/perfusion lung 
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scintigraphy for PE and doppler ultrasonography for suspected DVT. In 10 patients with 
suspected DVT, the only radiography consisted of lower-limb vein compression 
ultrasonography (CUS), performed at the emergency department 
3.1.2 Thrombophilia (Study III and V) 
Study III and V compounded the KUL thrombophilia study, a cross-sectional descriptive 
study. All adult patients that were subject to thrombophilia investigation at the special 
coagulation lab between 2014-2016 were invited to participate. Inclusion criteria were 
chosen to represent patients with a clinically robust indication for thrombophilia testing. 
After exclusions there were 369 patients, which were 166 with the inclusion criteria of 
personal history of VTE < 50 years of age, 153 with at least one first grade relative with 
VTE < 50 years of age and 50 with both of those inclusion criteria. A flow chart of the 
plasma samples that were included in study III is presented in Figure 11. Medical history 
was obtained from standardized forms filled out by the patient at the time of the written 
consent. The forms included gender, age, smoking, diabetes, pregnancy, BMI, family 
history of VTE and use of prothrombotic hormonal contraceptives or anticoagulant 
medication. Additional data and data verification were retrospectively assembled from 
electronical medical records, including details of any VTE, detailed family history of VTE, 
acquired risk factors for VTE, medication and results of thrombophilia investigation.  
 
 
 
 
 
 
 
 
 
2188 
invited
1085
consent
195 
no plasma available
180
cases 
6 samples
excluded before 
analysis
ETP 
5 samples
excluded
169
ETP results
OCP
5 samples
excluded
2 excluded assay
problems
167 
OCP results
OHP
5 samples
excluded
3 excluded assay
problems
166 
OHP results
OFP 
5 samples
excluded
5 excluded assay
problems
164 
OFP results
369
included
Figure 11. Flow chart of samples in study III 
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Study III was an evaluation of global hemostatic assays in patients investigated for 
thrombophilia. Result of the thrombophilia investigation were collected from the laboratory 
information system. The samples were additionally analyzed for the previously described 
variants in FGG, F11 and ABO (non-O), Table 3. 
Verifiable conventional thrombophilia was divided into; moderate thrombotic risk: protein 
C < 0.6 kIU/L, protein S < 0.5 kIU/L, antithrombin < 0.7 kIU/L, lupus anticoagulant >1.4 
in normalized dRVVT- or aPTT-quote or homozygous FVL or FII c.20210G>A . Mild 
thrombotic risk: heterozygous FVL and/or FII c.20210G>A  90. In the expanded genetic 
panel (FVL, F2, FGG, F11 and ABO), thrombophilia was defined as ≥ 3 risk alleles 93.  
Study V was an evaluation of a commercial clinical genetical risk algorithm (CGRA), TiC 
104. The CGRA includes 12 variants (Table 2) together with the clinical parameters; age, 
gender, BMI, smoking, diabetes and family history of VTE. In women, it incorporates 
pregnancy and treatment with prothrombotic hormonal contraceptives. A global risk value 
is calculated with the use of risk coefficients assigned to each risk factor in the algorithm, 
with adjustment for certain combinations. The risk coefficients are based on published 
information and meta-analyses (supplemental material of 104). TiC was also compared to 
purely genetic risk scores (GRS) and other CGRA. 
Variant  SNP 
TiC risk 
coefficient  
OR 
F5 (Leiden, G/A) rs6025 1.589 (htz) 3.79 
F2 (20210 G/A) rs1799963 0.293 (htz) 2.78 
ABO non-O (G/del) rs8176719  1.85 
FGG (C/T) rs2066865 0.344 (hmz) 1.56 
F11 (C/T) rs2036914 0.293 (htz) 1.32 
F5 (Hong Kong A/G) rs118203905 1.589 (htz) - 
F5 (Cambridge G/C) rs118203906 1.589 (htz) - 
F12 (C/T) rs1801020 1.633 (hmz) 5.12 
F13 (G/T) rs5985 0.198 (hmz) 0.82 
AT (Cambridge II G/T) rs121909548 2.277 (htz) 1.20 
Prot Z dependent inh (C/T) rs2232698 1.358 (htz) 3.98 
 
ABO A1 
rs7853989 
0.956 1.88 – 2.61 rs8176743 
rs8176750 
Table 2. Comprehensive summary of analyzed SNPs, adapted from Hinds et al 86, Vasan et 
al 98, Soria et al. 104 and Croles et al 106. Risk alleles in bold letters. 
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3.1.3 Mixed venous and arterial thrombosis cohort (Study IV) 
Study IV was an investigation of a novel 
prothrombotic genetic variant, FII c.1824C>T 
(rs3136532). The study was planned to also 
include a confirmation study in the KUL 
thrombophilia cohort, but the confirmation 
study is instead being performed separately and 
is not included in this thesis. Hence, the cohort 
in study IV is the Belgrade cohort which was 
assembled by I. Pruner. The 489 cases were 
included from a database of 4500 patients 
referred for routine thrombophilia screening 
(2002–2016), Figure 12. Inclusion criteria were 
personal history objectively documented DVT, 
pulmonary embolism or cerebrovascular insult. 
Cases and healthy controls were genotyped for 
FII c.1824C>T . Phenotype characterization 
was then performed in six cases with 
heterozygous FII c.1824C>T , six with 
heterozygous FII c.20210G>A  and 11 controls 
without FII c.20210G>A  or FII c.1824C>T . 
Characterization consisted of routine 
coagulation assays, prothrombin levels, global 
hemostatic assays and fibrin clot 
characterization.  
3.1.4 Healthy controls 
Healthy medical students were enrolled for analysis of ETP (n = 38), OHP (n = 42) and 
fibrinogen (n = 42). The controls were used to verify the observation that both cases and 
controls included from the emergency department displayed hypercoagulable profiles. They 
were also used to calculate 95th percentile ranges for the 2019 modification of the OHP for  
study III 166. Healthy blood donors were also collected for study IV and V. For study IV, 
432 Serbian donors, with no thrombotic disorder, family history or known thrombophilia. 
For study V, 100 Swedish donors, with no thrombotic disorder, family history or 
anticoagulant medication, age- and sex-matched to the KUL thrombophilia cohort.  
Figure 12. Flow chart of samples in study IV. 
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3.2 PREANALYTICAL PROCEDURES 
D-dimer, FM and PT (INR) were analyzed in fresh platelet poor plasma (PPP) (0.109 mol/L 
(3.2%) Na-Citrate), whereas ETP, OHP, fibrinogen, PT(INR), aPTT, antithrombin were 
analyzed after storage of the same samples at -70ᵒ C and thawing in a 37° C water-bath. 
Plasma for the thrombin generation assay was not separately collected and, accordingly, no 
Corn Trypsin Inhibitor was added at sampling 133, as per the proprietary instructions for the 
ETP 130, 136.  
DNA was extracted from leukocytes in EDTA blood by digestion and selective 
precipitation with ethanol on an automated QiaCube system using the QIAamp DNA-blood 
mini kit (Qiagen, Düsseldorf, Germany) and stored at -20°C. 
Sample aliquotation and storage for study II was performed within one hour after analysis, 
in the acute clinical chemistry lab in parallel with routine operations. More than 2200 
aliquots were stored and a subset of these were used for study II. Because sample collection 
was performed in a routine clinical chemistry laboratory where storage of research samples 
could not be the main priority, only a subset of samples from study I could be saved for 
analysis by FM in fresh plasma and stored for study II. In study II we included all samples 
with VTE and randomly selected age- and sex-matched samples without VTE. All included 
samples that were available (that had been stored) were analyzed by ETP and OHP (n=174; 
62 VTE and 112 without VTE). After exclusions 158 samples remained. 
Samples for the KUL thrombophilia cohort were initially collected and handled in the 
routine preanalytical pathway of the Karolinska University Laboratory, accredited 
according to ISO15189 by the Swedish Board for Accreditation and Conformity 
Assessment. After written informed consent was obtained, the 250 patients who fulfilled 
the inclusion criteria were stored in the study biobank if their blood samples were not yet 
discarded (i.e. within two months of arrival to the clinical lab).  
Samples for study V were collected specifically for the study. All subjects were without 
anticoagulant therapy and without thrombotic events within 6 months prior to sampling. 
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3.3 ASSAYS  
D-Dimer, FM and PT (INR) were analyzed on a Sysmex CS-2100i (Siemens Healthcare 
Diagnostics, Erlangen, Germany), except Stagos STA®-Liatest® D-Di Plus which was 
analyzed on the Stago CompactMax (Diagnostica Stago, Asnières-sur-Seine, France). ETP, 
Protein C, protein S, lupus anticoagulant and Factor II activity was analyzed on the BCS® 
XP instrument (Siemens). Fibrinogen, antithrombin and aPTT were analyzed on the 
Sysmex CS-5100 (Siemens) and CRP was analyzed on the Cobas 6000 instrument (Roche 
Diagnostics, Basel, Switzerland). All assays were calibrated with proprietary calibrators. 
3.3.1 Fibrin degradation products (Study I-III) 
D-dimer and FM were analyzed by rapid particle-enhanced immunoturbidimetric assays; 
Roche Tina-quant D-dimer (Roche Diagnostics), Siemens INNOVANCE® D-dimer 
(Siemens), Medirox MRX D-dimer (MRX143) (Medirox, Nyköping, Sweden) and STA®-
Liatest® D-Di Plus and STA®-Liatest® FM (Diagnostica Stago). Cutoffs and number of 
samples tested are presented in Table 3.  
3.3.2 Routine coagulation and chemistry assays (Study I - IV) 
PT (INR) was analyzed by MRX Owrens PT  (Medirox). Fibrinogen was analyzed using 
the Dade® Thrombin Reagent (Siemens) which is a modified Clauss assay. Antithrombin 
was analyzed with the Factor II-based Berichrom® Antithrombin III (Siemens) in study II 
and IV and by the Factor Xa-based Innovance® Antithrombin assay (Siemens) in study III. 
Activated partial thromboplastin time (aPTT) by PTT-Automate (Diagnostica Stago) and 
CRP by the immunoturbidimetric CRPL3, C-Reactive Protein Gen. 3 assay. 
3.3.3 Thrombophilia assays (Study I - IV) 
Protein C was analyzed using the enzymatic Berichrom® Protein C assay (Siemens), free 
protein S was analyzed using the Innovance Free PS Ag (Siemens) and lupus anticoagulant 
was analyzed according to the ISTH guidelines 167 using the following reagents: diluted 
 Samples Cutoff 
Age adjusted    
cutoff 
Tina-quant D-Di 939 <0.50 mg/L FEU Age x 0.01 
Innovance D-Di 871 <0.50 mg/L FEU Age x 0.01 
MRX D-Di 819 <0.20 mg/L Age x 0.004 
STA-Liatest D-Di 170 <0.50 mg/L FEU Age x 0.01 
STA-Liatest FM 119 <6 mg/L - 
Table 3. Details of D-dimer assay cutoffs. 
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Russel viper venom time (dRVVT) by LA Screen and LA confirm (Life Diagnostics, West 
Chester, Pennsylvania, USA), PTT-LA (Diagnostica Stago, Asnières-sur-Seine, France) 
and Actin FS PTT (Siemens).  
To avoid false positive thrombophilia classification, results were excluded in case of low 
protein C or S from subjects on warfarin medication, protein S from pregnant patients, low 
antithrombin from patients on direct oral F Xa-inhibitors or positive lupus anticoagulant 
from patients on anticoagulant, if they had not been verified after 12 weeks in a sample 
without medication.   
3.3.4 Prothrombin in plasma (Study IV) 
Prothrombin (FII) activity was determined using the Dade® Innovin® Reagent with factor 
II-deficient plasma (Siemens) and FII protein concentration was determined using the 
Human Prothrombin ELISA kit (Nordic BioSite, Täby, Sweden).  
Relative plasma FII levels were also quantified by western blot in triplicate in three 
separate experiments. The samples were separated on 12% SDS–PAGE and transferred to a 
polyvinylidene fluoride membrane (PVDF, Millipore®, Sigma Aldrich, St. Louis, Missouri, 
United States). Thrombin K-20 goat polyclonal was used as the primary antibody (Santa 
Cruz Biotechnology, Dallas, Texas, United States) and anti-goat IgG conjugated with 
peroxidase (Sigma Aldrich) as the secondary antibody. Immunoreactive bands dyed with 
chemiluminescent ECL blotting reagents (Millipore®). The signal was relatively quantified 
by densinometry in the Image Studio Lite (LI-COR Biosciences, Lincoln, Nebraska, United 
States) and normalized against standard human plasma.  
3.3.5 Global hemostatic assays (Study II, III and IV) 
Thrombin generation was analyzed using the automated Innovance® ETP assay with the 
proprietary B-settings for hypercoagulable patients, where thrombin generation is restricted 
to the extrinsic coagulation by using Tissue Factor in high concentration (300 pM) as an 
activator 137. The assay includes an unnamed fibrin aggregation inhibitor and a slow 
reacting chromogenic thrombin substrate (H-β-Ala-Gly-Arg-pNA).  
The OHP was analyzed with CaCl2, 0.04 U/mL thrombin and 300 ng/mL t-PA and the two 
separate protocols for clinical laboratories. The 2001 protocol 161 was used in study II and 
the OCP, OHP and OFP in study IV. The 2019 protocol 166 was used in III and for the 
turbidity times in study IV. The ETP results and OHP results from study III were 
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normalized against standard human plasma, giving results in %. Intra-assay and inter-assay 
CV% for the ETP were 3.3% and 2.7% respectively. Intra-assay and inter-assay variation 
coefficient (CV%) for the OHP were 9.3% and 12.3%. 
3.3.6 Fibrin clot characterization (Study I-IV) 
Samples from study IV were analyzed by SEM to visualize the structure of fibrin networks 
in FII c.1824C>T . Patient plasma was mixed with CaCl2 (1 mol/L) and 0.05U/mL of 
thrombin and transferred to plastic tubes before incubation in a humidity chamber. The 
clots were washed for 30 min in PBS, fixed in 2% glutaraldehyde for 60 min at room 
temperature and then stored at 4°C. The specimens were rinsed in distilled water and placed 
in 70% ethanol/10 min, 95% ethanol/10 min, absolute ethanol/15 min, pure acetone/10 min 
and then transferred to tetramethylsilane (Merck) for 10 min and air-dried. After drying, the 
specimens were mounted on an aluminum stub, coated with carbon (Bal-Tec MED 010) 
and analyzed in an Ultra 55 field emission scanning electron microscope (Carl Zeiss) at 3 
kV. For each sample, 50 individual fibers were randomly selected for measurement of 
thickness using SIS iTEM software (FEI Company, Hillsboro, Oregon, United States).  
Samples from the VTE and thrombophilia cohorts were prepared for analysis of fibrin 
networks by confocal microscopy and SEM. A subset of samples from the VTE-cohort 
were investigated by fibrin clot permeability, but fibrin clot characterization of these 
cohorts was removed from the doctoral project and will be presented separately.   
3.3.7 Genotyping Prothrombotic variants (Study III, IV and V) 
Genotyping of the variants FVL (rs6025), FII c.20210G>A  (rs1799963), ABO non-O 
(rs8176719), FGG (rs2066865) and F11 (rs2036914) were performed by TaqMan SNP 
Genotyping Assays in the ABI 7500 Fast Real-Time System (Applied Biosystems, Foster 
City, California, United States)  Genotyping of the variants included in the TiC panel were 
performed at the genetics lab of Sant Pau Hospital (Barcelona, Spain) using KASPar, 
Competitive Allele Specific PCR SNP genotyping system (KBiosciences, Hoddesdon, 
United Kingdom). Cases and controls from study IV were tested for FII c.1824C>T 
(rs3136532), FVL and FII c.20210G>A  restriction fragment length polymorphism (RFLP) 
to determine the EAF. FII c.1824C>T was additionally genotyped by sanger sequencing. 
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3.3.8 Gene expression in transfected cell cultures (Study IV) 
Wild-type full-length F2 cDNA was cloned in the pCI-neoΔSV40 vector, which promotes 
constitutive expression of cloned DNA inserts. For stable expression of the genes, the 
vector was co-transfected with an expression vector and the neomycin resistance gene was 
employed as a reference gene. The FII 20210A and FII 1824T  variants were introduced by 
site-directed mutagenesis, also resulting in stable expression. The Cos-7 cells were 
cultivated for 4 weeks in conditioning medium with G418 (1 mg/mL) and stored in liquid 
nitrogen after harvest. 
The level of prothrombin mRNA was determined by reverse transcription - real time PCR 
(RT-qPCR), using the TaqMan allelic discrimination method in the Applied Biosystems 
7500 Real-Time PCR system. Total mRNA was isolated using the Qiagen RNeasy Plus 
Mini Kit (Qiagen) and reverse transcribed to cDNA with a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Results were analyzed by software provided with 
the ABI Prism 7500 Sequence Detection System (Applied Biosystems). The relative 
mRNA concentration was compared between transfected and wild-type cells.  
Effects of Prothrombin Belgrade on the mRNA secondary structure were predicted in silico  
3.4 ETHICAL AND LEGAL ASPECTS 
All studies were conducted in accordance with the Declaration of Helsinki and all 
participants provided a written informed consent at enrolment. Studies I-III and V were 
approved by the regional ethics review board in Stockholm (DNR 2013/2143-31 and 
2014/987-31).  Study IV was approved by the local ethics committee at the Institute of 
Molecular Genetics and Genetic Engineering, University of Belgrade (O-EO-004/2015/2). 
The Swedish samples were registered as sample collections in the Stockholm Medical 
Biobank. The personal data processing databases were registered at Karolinska University 
Hospital. When the pseudonymized database was shared with the Spanish diagnostics 
company of FerrerInCode for analysis in study IV, the data was pseudonymized a second 
time. The transfer of data and genetic material was detailed in a Material Transfer 
Agreement (MTA) and a Personal Data Processors Agreement (PDPA) that was drafted 
between Karolinska Institutet, Stockholm Medical Biobank and FerrerInCode. All samples 
were discarded after analysis in Spain, as specified in the MTA and a separate attestation of 
sample destruction.  
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4 RESULTS  
4.1 PATIENTS WITH SUSPECTED ACUTE VTE (STUDY I AND II) 
4.1.1 Evaluation of age-adjusted D-dimer cutoffs 
All D-dimer assays had AUCs ≥0.9, the diagnostic performance is displayed in Table 5 and 
Figure 13. The sensitivities of all assays were high, with only six cases falsely classified as 
negative by any assay. When age adjusted cutoffs were applied, all assays maintained their 
sensitivities and the specificities increased by 6-7%.  
 
 AUC 
(95% CI) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
NPV % Neg % FP 
Tina-quant 
D-Di 
0.93 (0.91-0.95) 
- 
0.98 (0.95-1.00) 
0.98 (0.95-1.00) 
0.63 (0.59-0.66) 
0.69 (0.66-0.72) 
0.99 
0.99 
55% 
60% 
32% 
27% 
Innovance 
D-Di 
0.92 (0.89-0.95) 
- 
0.96 (0.93-1.00) 
0.96 (0.93-1.00) 
0.61 (0.58-0.65) 
0.68 (0.64-0.71) 
0.99 
0.99 
53% 
59% 
34% 
28% 
MediRox    
D-Di 
0.90 (0.87-0.94) 
- 
0.94 (0.90-0.99) 
0.94 (0.90-0.99) 
0.66 (0.62-0.69) 
0.72 (0.69-0.76) 
0.99 
0.99 
58% 
64% 
30% 
24% 
STA-Liatest 
D-Di  
0.89 (0.82-0.96) 
- 
0.96 (0.89-1.00) 
0.96 (0.89-1.00) 
0.51 (0.43-0.59) 
0.58 (0.50-0.66) 
0.99 
0.99 
43% 
49% 
41% 
35% 
Table 5. Diagnostic performance of the four D-dimer assays, comparison of proprietary 
cutoffs and age-adjusted cutoffs for each assay in 954 patients.  
Figure 13. Cumulative data analysis of Tina-quant D-dimer, similar curves for all assays. 
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The decrease in number needed to test was also modest; 0.15-0.27 for the respective assays. 
The false positive results decreased by 5-6 percent units, with a corresponding increase in 
negative results for all assays as those false positives became true negatives. The decrease 
in % FP increased by age, in patients ≥ 80 years it decreased by up to 20%, see Figure 14. 
In patients < 50 years, no adjustment of the proprietary cutoff was applied. D-dimer 
analyzed by Tina-quant displayed a sensitivity of 0.91 (0.82-1.01, 95% CI) and specificity 
0.82 (0.78 – 0.86) in patients < 50 years (n = 346). 
Figure 14. Difference between proprietary and age-adjusted cutoff, presented as a 
percentage of the total VTE occurrence and percentage of positive results in each age 
group. For each age group, n is designated in parenthesis. 
4.1.2 Global hemostatic assays in patients with venous thromboembolism 
All OHP and ETP parameters as well as fibrinogen demonstrated hypercoagulable profiles, 
with significant differences in medians compared to healthy controls, see Figure 15 . 
Significant differences between patients with and without VTE were found in D-dimer and 
FM (p < 0.005), ETP Tlag (p = 0.031) and for ETP AUC (p = 0.001), where the mean for 
VTE was 99% and non VTE 107%. Assessment of the relationship between ETP AUC and 
OHP levels in these clinical subgroups showed no trends in relation to VTE status.           
  
Figure 15. Global hemostatic parameters in patients with no VTE [white], VTE [grey] and 
healthy controls [light grey]. Reference lines at 95th percentile reference ranges.  
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The diagnostic performance of the parameters of the OHP and ETP assays compared to 
Tina-quant D-dimer and FM is presented in Figure 16 and Table 6. The parameters of OHP 
and ETP had ROC AUCs ≤0.65. The specificities ranged from 0.0-0.2 at the respective 
cutoff where the sensitivity of each parameter was in accordance with CLSI H59-A and 
equal to the sensitivity of D-dimer (0.97 at the cutoff 0.5 mg/L FEU). 
 
 
 
 
 
 
 
 
 
 
Figure 16. Diagnostic performance in discrimination of acute VTE presented as ROC-
curves for D-Di, FM, ETP and OHP. ETP Tmax is negative because it is the only parameter 
where a smaller test result indicates a more “positive” test  
Parameter 
ROC AUC 
(95% CI) 
Cutoff Sensitivity Specificity 
 
OHP [Abs Sum] 0.50 (0.40 - 0.60) 7 0.97 0.04  
OCP [Abs Sum] 0.55 (0.45 - 0.65) 12 0.97 0.00  
OFP [%] 0.56 (0.47 - 0.65) 17 0.97 0.09  
ETP AUC [%] 0.65 (0.56 - 0.74) 85 0.97 0.20  
ETP Cmax [%] 0.57 (0.48 - 0.67) 90 0.97 0.13  
ETP Tlag [sec] 0.60 (0.51 - 0.70) 15 0.97 0.02  
ETP Tmax [sec] 0.43 (0.33 - 0.52) 42 0.97 0.01  
D-dimer [mg/L FEU] 0.94 (0.90 - 0.97) 0.5 0.97 0.66  
Fibrin Monomers [mg/L] 0.76 (0.68 - 0.85) 
0.9 
6.0 
0.97 
0.57 
0.20 
0.84 
 
 
 
Table 6. Areas under the ROC curve and accuracy parameters at the cutoff fulfilling 
CLSI H59-A. For FM the proprietary cutoff is also presented. 
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Figure 17. Assay result dispersion for a) ETP AUC and ETP Cmax and b) OCP and OFP related 
to type of anticoagulant medication. Reference lines at 95th percentile reference ranges. 
 
  
n = 88      n = 14     n = 26      n = 6        n = 2        n = 34 
n = 88        n = 14      n = 26        n = 6         n = 2         n = 34 
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4.2 PATIENTS INVESTIGATED FOR THROMBOPHILIA (STUDY III AND V) 
4.2.1 Global hemostatic assays in thrombophilia investigation 
Plasma from 174 patients were available for statistical analysis in study III, see Figure 11. 
The FH group had a lower median age, compared to the other groups, with a high 
proportion of females and pregnancies (40% of female participants). Anticoagulant 
medication was present in ≥80% of patients in the VTE groups, but 6% in the FH group. 
Hypercoagulability profiles are presented in Figure 17 and Table 7. There were no 
significant differences between the distributions of the clinical indication groups (VTE, 
VTE+FH, FH). Increased risk of venous thrombosis was demonstrated by GHA in 59 
patients (34%) with 17 patients (10%) that showed increased thrombotic risk in both GHA 
and the conventional thrombophilia panel. Only 3 of the 14 patients with verifiable 
moderate-risk thrombophilia were identified by the global hemostatic assays; two patients 
homozygous for FVL that had  increased thrombin generation and one patient with APS 
and decreased fibrinolysis in the OHP assay. There were no robust correlations between the 
global hemostatic assays and verifiable thrombophilia, although notably there were only 26 
thrombophilia patients without anticoagulant medication.  
The conventional thrombophilia demonstrated increased risk of VTE in 54 (31%), where 14 
patients (8%) were at moderate risk and 40 patients (23%) had only a mildly increased risk 
of VTE. The addition of three more SNPs to the conventional panel increased the number 
of patients with a verifiable increased risk of thrombosis, n = 67. The extended 
thrombophilia panel demonstrated 90 patients (52%) with 3-4 risk alleles, 21 (12%) with 5-
6 risk alleles and 10 (6%) with biochemical markers of thrombophilia.   
In total, 84 patients had anticoagulant medication at the time of sampling and 90 did not. 
Preliminary results show that the median number of days since last VTE was 21 (IQR 4 – 
156 days). We tried to objectify the extent of samples taken in suboptimal preanalytical 
conditions by quantifying the proportion of common preanalytical pitfalls. We found that 
lupus anticoagulant had been ordered in 82% of samples receiving anticoagulant 
medication, antithrombin analyzed by FXa-method had been ordered in 67% of patients 
receiving Factor Xa-inhibiting DOACs, protein C had been ordered in 86% of patients 
receiving warfarin and that protein S had been ordered in 62% of pregnant patients. 
 
 
 40 
 
 
Total VTE VTE + FH FH 
(n = 174) (n = 83) (n = 19) (n = 72) 
Global hemostatic assays, n positive (p) 
      
ETP AUC (n = 169) 16 (0.09) 8 (0.10) 3 (0.16) 5 (0.07) 
ETP Cmax               (n = 169) 22 (0.13) 11 (0.14) 3 (0.16) 8 (0.11) 
OCP (n = 167) 23 (0.14) 10 (0.13) 2 (0.11) 11 (0.15) 
OHP (n = 166) 22 (0.13) 8 (0.10) 6 (0.33) 8 (0.11) 
OFP (n = 164) 21 (0.13) 14 (0.18) 5 (0.28) 2 (0.03) 
Any GHA (n = 174) 59 (0.34) 30 (0.36) 7 (0.37) 22 (0.31) 
Verified thrombophilia, n positive (p)   
Moderate risk (PC, PS, AT, 
APS, hmz FVL) 
14 (0.08) 6 (0.07) 3 (0.16) 5 (0.07) 
Mild risk (htz FVL and/or 
FII c.20210G>A) 
40 (0.23) 18 (0.22) 7 (0.37) 15 (0.21) 
Five SNPs (≥ 3 risk alleles) 116 (0.67) 54 (0.65) 15 (0.79) 47 (0.65) 
Biochemical markers, n positive (n tested) 
      
Lupus anticoagulant  7 (120) 3 (66) 2 (14) 2 (33) 
Protein C deficiency 1 (167) 0 (79) 0 (17) 1 (71) 
Protein S deficiency 1 (143) 0 (79) 0 (17) 1 (47) 
Antithrombin deficiency  1 (138) 1 (67) 0 (13) 0 (58) 
Genetic analyses, EAF         
Factor V Leiden  0.12 0.11 0.21 0.11 
FII c.20210G>A   0.04 0.06 0.03 0.01 
Factor XI  0.59 0.60 0.55 0.58 
Fibrinogen γ 0.29 0.28 0.32 0.28 
ABO non-O 0.49 0.45 0.53 0.51 
Coagulation lab, median (n) (IQR)        
PT (INR)  0.9 (73) 1.0 - 1.0 1.0 (41) 0.9 - 1.0 1.0 (11) 1.0 - 1.0 0.9 (24) 1.0 - 1.0  
Fibrinogen 2.5 (32) 3.2 - 4.2  3.3 (16) 2.5 - 3.3 4.3 (3) - 3.1 (13) 2.6 - 4.1 
Table 7. Thrombophilia investigations. False positive results due to preanalytical factors 
were excluded. Biochemical results only classified as positive in verified positives (methods)  
 
AT: Antithrombin, EAF: effect allele frequency, FH: Family History of VTE <50               
FVL: Factor V Leiden, LA: Lupus Anticoagulant, n: count, p: proportion, PC: Protein C, 
PS: Protein S, VTE: Venous thromboembolism 
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4.2.2 Diagnostic accuracy of a commercial thrombophilia panel  
In the evaluation of the commercial clinical/genetic risk algorithm (CGRA) TiC, there were 
147 cases (48% female) and 143 controls (73% female), since in the diagnostic accuracy 
evaluation, the patients with no personal history of VTE (n = 43) were counted as controls 
together with healthy controls from the blood bank (n = 100).  
 VTE No VTE  
Variant n = 147 n = 143 p value 
F5 Leiden 35 (23.81) 22 (15.38) 0.0714 
FII c.20210G>A 11 (7.48) 3 (2.10) 0.0329 
F11 120 (81.63) 120 (83.91) 0.6080 
FGG 83 (56.46) 64 (44.75) 0.0465 
F5 Hong Kong 0 0  
F5 Cambridge 0 0  
F12 68 (46.26) 71 (49.65) 0.5641 
F13  58 (39.45) 75 (52.45) 0.0266 
AT (II Cambridge) 4 (2.72) 0 0.0474 
ZPI (p.R67X)  0 0  
ABO A1 haplotype 84 (57.14) 56 (39.16) 0.0022 
Table 8. Presence of effect allele variants (≥1 alleles) in individuals with and without 
previous VTE, N (%). A1 haplotype of ABO blood group; if  ≥1 predisposing allele in 3 SNPs.  
Table 8 shows the frequency of risk polymorphisms. The ABO A1 haplotype alleles were 
significantly more frequent in patients with VTE than without VTE. The presence of at 
least one risk allele in the genes for prothrombin, antithrombin and the fibrinogen γ chain 
were also significantly more frequent in patients with previous VTE. The protective allele 
in the gene for FXIII was significantly less common in patients with VTE. There were no 
significant differences in the frequency of FVL or the risk alleles in the genes for FXI, FXII 
or antithrombin. There were no instances of F5 Hong Kong, F5 Cambridge or the nonsense 
variant in ZPI.  
The prognostic characteristics of all genetic risk scores (GRS) and CGRA are shown in 
Table 9. TiC ® had significantly better discriminative capacity (AUC) than FVL+F2 (0.71 
vs 0.57, p < 0.0001), but non-significance in the comparison of only the genes in TiC and 
FVL+F2 (0.61 vs 0.57, p = 0.290). The AUC of TiC was significantly higher than 
FVL+F2+clinical factors (0.71 vs 0.65, p = 0.012).  
The clinical variables alone had a significantly higher AUC than FVL+F2 (0.660 vs 0.566, 
p=0.0026). The addition of F11 and FGG to did not significantly improve the AUC of the 
TiC GRS (0.63 vs 0.61, p = 0.195) or the TiC CGRA (0.65 vs. 0.71, p=0.054).   
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4.2.3 Characterization of a novel prothrombotic variant 
The characterization of FII c.1824C>T included 489 cases (370 VTE, 119 cerebrovascular 
insult (CVI)) of which 190 had family history of thrombosis. The frequency of FII 
c.1824C>T  was increased in patients with VTE and CVI compared to controls and the 
variant increased the OR for thrombotic events significantly, Table 10. EAF of FV Leiden 
and FII c.20210G>A  were consistent with previous studies in Serbian population 168.  
The predictive modelling indicated a change in the mRNA secondary structure; a bulge in 
the wild-type secondary structure disappeared when a bulge, caused by an unpaired 
adenosine, disappeared after substitution to uracil (C>T in DNA). The levels of mRNA 
expression (FII-c.1824T and FII-c.20210A) in transfected cell culture were determined 
relative to mRNA expression in transfected cells expressing wild-type prothrombin (FII-
wt), Figure 18A. Relative levels of FII mRNA expression were significantly increased 
(p<0.05); 1.65 for FII-c.20210A transfectants and 1.64 for FII-c.1824T.  
The prothrombin activity measured by clot time was unaffected by FII c.1824C>T, and FII 
concentration measured by ELISA showed only a non-significant tendency towards 
increased FII levels. In the sensitive western blot assay, prothrombin levels (detected at 70 
kDa) were significantly increased compared to controls (p<0.05), Figure 18B. Normalized 
to standard normal plasma, FII levels were 1.44 ± 0.25 in FII c.1824C>T and 1.63  ± 0.22 
in FII c.20210G>A .  
Variants 
Controls VTE CVI 
(n = 432) (n = 370) (n = 72) 
FII c.1824 C>T    
Variant carriers, n (EAF) 4 (0.01) 11 (0.03) 5 (0.04) 
p-value (vs. controls)  0.038* 0.026* 
OR (95% CI)  3.28 (1.04 - 10.39) 4.69 (1.24 - 17.76) 
FII c.20210 G>A     
Variant carriers, n (EAF) 28 (0.07) 39 (0.11) 3 (0.03) 
p-value (vs. controls)  0.040* 0.110 
OR (95% CI)  1.70 (1.02 - 2.82) 0.37 (0.11 - 1.25) 
FV Leiden G>A     
Variant carriers, n (EAF) 16 (0.04) 81 (0.22) 12 (0.10) 
p-value (vs. controls)  < 0.0001* 0.007* 
OR (95% CI)  7.3 (4.2 - 12.7) 2.9 (1.3 - 6.3) 
Table 10. Variant frequencies and odds ratios in control patients and patient subgroups 
VTE and CVI. Risk alleles in bold letters. 
*: significance EAF: Effect allele frequency (%), CI: Confidence interval, n: count,               
p-value: probability value, VTE: venous thromboembolism, CVI: cerebrovascular insult 
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Figure 18. (A) mRNA expression in FII wild-type vector, and cells transfected with the FII-
c.1824T and FII-c.20210A vectors.* p < 0.05.(B) Western blot of FII levels in plasma 
(lanes 1-3: triplicate sample, lane 4: negative control. (i) standard human plasma; (ii) 
healthy noncarriers; (iii) FII c.20210G>A  carriers, and (iv) FII c.1824C>T carriers.  
Scanning electron microscopy of 
fibrin clots from c.1824C>T carriers 
revealed denser clots with thinner 
fibers (median 129 nm, IQR 80 nm) 
compared to clots formed in plasma 
of FII c.20210G>A  carriers (median 
152 nm, IQR 59 nm) and healthy 
noncarriers (median 159 nm, IQR 72 
nm) (P<0.05). There were also an 
increased numbers of branch points 
and smaller intrinsic pores than in 
fibrin clots from healthy noncarriers, 
see figure 19. 
Figure 19. Representative SEM of fibrin clots.  
Black scale marker; 6 μm in left image, 1.2 μm in right 
A: Controls, B: FII c.1824C>T , C: FII c.20210G>A . 
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The routine coagulation assays were unaffected by the variant, except for a significantly 
decreased mean aPTT, within the reference range (Δ 4s, P<0.05). The OFP was decreased 
in FII c.1824C>T  and clot lysis time was increased, Table 11. In FII c.20210G>A , it was 
instead the ETP AUC and Cmax that were significantly increased.  
 
 
Healthy 
controls 
n=11 
FII 
c.1824C>T 
carriers 
n=6 
FII 
c.20210G>A  
carriers 
n=6 
Controls vs. 
FII 
c.1824C>T 
carriers 
Controls vs. 
FII 
c.20210G>A  
carriers 
Global hemostatic assays, Mean (SD) P P 
ETP AUC 
87.82 
(10.65) 
93.67 (13.85) 108.67 (6.50) 0.345  0.001 * 
ETP Cmax 88.91 (6.82) 91.50 (10.39) 114.17 (8.33) 0.542 <0.001 * 
OCP 18.98 (5.22) 23.44 (5.68) 21.07 (5.74) 0.123 0.459 
OHP 11.01 (4.33) 15.51 (4.67) 13.05 (5.24) 0.065 0.401 
OFP 43.40 (8.64) 34.53 (6.66) 39.49 (10.18)  0.046 * 0.414 
Coagulation (turbidity), Median (IQR) P P 
Lag time (min) 3.60 (2.00) 4.10 (1.80) 3.60 (1.60) 0.960 0.573 
Max Abs 0.90 (0.36) 1.14 (0.45) 1.00 (0.44) 0.132 1.000 
Clotting rate (slope) 0.08 (0.02) 0.07 (0.02) 0.10 (0.07) 0.615 0.615 
Max Abs time (min) 6.40 (3.00) 7.00 (3.25) 5.80 (2.40) 0.338 0.546 
Slope time (min) 2.20 (1.20) 2.90 (1.35) 2.10 (1.55) 0.069 0.541 
Fibrinolysis (turbidity), Median (IQR) P P 
Lag time (min) 4.40 (1.40) 4.40 (1.30) 3.80 (1.35) 0.723 0.312 
Max Abs 0.92 (0.41) 1.13 (0.45) 1.03 (0.41) 0.512 1.000 
Clotting rate (slope) 0.08 (0.02) 0.08 (0.03) 0.10 (0.06) 0.688 0.421 
Max Abs time (min) 7.20 (2.40) 7.10 (2.95) 6.10 (2.25) 0.512 0.246 
Slope time (min) 2.60 (0.80) 2.70 (1.65) 2.10 (1.50) 0.358 0.266 
Lysis time (min) 23.13 (7.80) 27.40 (7.20) 23.00 (11.85)  s0.044 * 0.687 
 
Table 11. Parameters of thrombin generation, fibrin aggregation, coagulation times and fibrinolysis 
times in controls and carriers of FII c.20210G>A  and FII c.1824C>T .  
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DISCUSSION 
4.3 ACUTE VENOUS THROMBOEMBOLISM 
Our prospective single-center study supported the use of age-adjusted cutoffs for D-dimer 
in patients with suspected acute DVT and PE. Age-adjusted cutoff resulted in improved 
specificity with maintained sensitivity for all evaluated D-dimer assays. We demonstrated 
that this personalized approach to D-dimer cutoffs lead to a significant decrease in the 
proportion of patients with false positive results, especially in the older population.  
Our objective in the cross-sectional study II was to compare the diagnostic value of D-
Dimer to thrombin generation and fibrin aggregation in plasma and FM acute VTE. We 
could confirm previous findings that ETP AUC and ETP Tlag were significantly increased in 
acute VTE. However, the discriminatory ability of D-dimer was superior to both FM and 
the global hemostatic assays. In essence, the global hemostatic assays demonstrated 
differences between patients with and without acute VTE that were insufficient for 
effective discrimination and no useful cutoff could be identified for any of the parameters. 
Moreover, we demonstrated a poor tradeoff between sensitivity and specificity for FM.  
Our results further indicated that a large portion of the emergency patients were in a 
hypercoagulable state, possibly caused by an acute phase reaction, fibrinogen levels were 
significantly increased regardless of final VTE status. We also demonstrated generally 
increased coagulation potential (OCP) and decreased fibrinolytic potential (OFP), 
suggesting that the OHP assay may be unsuitable for exclusion of acute VTE in the 
emergency department. The use of thrombin generation assays in acute settings may also be 
prone to acute phase effects which have not been extensively evaluated yet, such as high 
levels of FVIII in patients with acute phase reactions, which is associated with a true 
increase in hypercoagulability, but might obscure findings related to acute thrombotic 
events. Another such issue that affects the accuracy of the thrombin generation assays is the 
existence of α-2-macroglobulin-thrombin complexes in plasma. It is possible that several of 
the patients in this study had abnormal levels of α2M, related to other pathology, which 
may have influenced the results of the ETP assay.  
4.3.1 Methodological considerations in study I 
The main limitation of the study was the lack of data on clinical pre-test probabilities of 
VTE in the patients. The study plan dictated that these would be retrospectively collected 
from medical records in the form of Wells scores. However, in data collection it became 
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apparent that Wells Scores were documented in a negligible share of the cases and that 
clinical data for a possible retrospective calculation of Wells scores was not widely 
available either. The problem of low comprehension of the study among the emergency 
department personnel including patients for the study could partly be explained by the rapid 
staff turnover at the emergency department. Since clinical pre-test probabilities could not be 
defined, the NPVs/PPVs and efficiencies calculated in this study cannot be individually 
applied as part of a risk algorithm to patients of high or low clinical suspicion This means 
that results have to be interpreted only on a general level. It might be argued that possibly 
the lack of documented clinical stratification could mean that assessments of VTE 
probability were to some extent performed by only clinical gestalt in the emergency 
department. In this case, general accuracy measurements could be of more direct relevance. 
It has also been suggested that D-dimer (<0.75 mg/L FEU) could be used without previous 
assessment of clinical pre-test possibility to exclude PE [33], however this has been 
evaluated in a meta-analysis where it could not be verified [34].  
Even though sensitivity was investigated in a group including patients with  high clinical 
probability, sensitivities were high. Furthermore, the false negative results were minor 
thromboses for all events bar one – i.e. subsegmental PEs and distal DVTs. These minor 
VTEs are classified as VTE negative in many studies, which increases sensitivity outcomes.  
Another key limitation was the fact that only 55% of the patients were investigated by the 
radiological reference methods. Total coverage would not have been feasible in this study 
and we decided to instead actively follow all patients in medical records and instruct the 
patients to return to the ED if symptoms remained. This research practice is not uncommon 
in evaluations of D-dimer but introduces the possibility of missing false negative cases. To 
ensure that no missed VTEs were neglected in the study, due to patients deceasing outside 
of hospital or contacting medical resources not connected to electronic medical records 
system (TakeCare). We extensively discussed and investigated the retrieval of morbidity 
and mortality data from national registries, to verify our excluded VTEs. Ultimately, the 
price and time of such an endeavor were deemed to be too costly. 
The limitation of study size was most pronounced for Stagos STA®-Liatest® D-Dimer, 
resulting in wider confidence intervals for this assay. We chose to include some results 
from Stago in spite of few samples, since it was possible to discern that the assay seemed 
comparable to the other three assays.  
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4.3.2 Methodological considerations of study II 
A strength of the study was that samples were handled exactly as real-life samples. We 
were able to include a large number of patients into the VTE study in just one year, because 
we could arrange for a study-specific analysis that could be electronically ordered from the 
medical information system (TakeCare). However, we still noticed a drastic decrease of 
inclusions to the study from the emergency department when the study had been active for 
one year, possibly caused by inclusion fatigue or staff turnover. A related problem was that 
since so many in the staff at the routine coagulation lab were involved in the preanalytical 
handling, it was very common to forget to aliquot and store samples. Hence, only a limited 
subset of samples could be analyzed with OHP and ETP in study II (Figure 10). We 
attempted to decrease the risk of clinical confounders by a rough matching for age before 
choosing controls at random from the stratified group in order to decrease the risk of 
selection bias by.  
Given our study size it was not possible to stratify patients with PE and proximal or distal 
DVT. Distal DVT was the main pathology in 32% of the patients with VTE, i.e. cases 
where surveillance is often recommended over anticoagulant treatment, though the vast 
majority are treated with anticoagulants 169. However, our results did not change when we 
excluded patients with distal DVT from the analysis. 
4.4 THROMBOPHILIA INVESTIGATION 
In study III, we aimed to explore the hypercoagulable profiles in clinical thrombophilia 
investigations. Despite frequent anticoagulant treatment, the patients investigated for 
thrombophilia had increased thrombin generation, fibrin aggregation or decreased 
fibrinolysis in 34% of cases. This was a discrete increase in hypercoagulable profiles from 
the conventional thrombophilia panel where 31% of patients had at least one pathological 
value, but where the majority of positive results were represented by heterozygous FVL or 
FII c.20210G>A .  
Thrombin generation assays and fibrin aggregation measured by turbidimetric assays have 
been proposed as screening assays for thrombophilia. The secondary aim of study III was to 
assess whether ETP and OHP could precede the conventional panel in thrombophilia 
investigations. Notably, the proportion of hypercoagulable ETP and OHP results were low 
in patients with verifiable thrombophilia and not correlated to the risk level of the 
thrombophilia. However, inherently hypercoagulable phenotypes were likely obscured by 
the high prevalence of anticoagulants. 
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In study V, the recognized problem of thrombotic risk stratification was reflected in the 
poor predictive abilities of the clinical factors and the evaluated GRS and CGRA. In 
accordance with previous studies, the ROC AUC of  the clinical factors was superior to 
FVL+F2, the TiC genes and to TiC+F11+FGG. The complete TiC CGRA had significantly 
better discriminative capacity than FVL+F2, but non-significance in the comparison of the 
genes in TiC vs. FVL+F2, which implied that the difference may be attributed to the 
clinical factors included in the TiC CGRA. In spite of geographic differences in EAF, the 
discriminative ability in our confirmation was similar to that of Soria et al 104, implying that 
TiC CGRA could be transferable to the Swedish population. As the notion of individual 
risk stratification without accounting for clinical factors seems clinically inapplicable, the 
more interesting comparison is that of the CGRA TiC to FVL+F2+ clinical factors. This 
comparison revealed a discrete but statistically significant increase of AUC in favor of TiC.  
In study IV, we could demonstrate a potentially prothrombotic phenotype of the novel 
sSNP FII c.1824C>T . Our in-silico prediction of the RNA secondary structure showed that 
the C>T change at position c.1824 can be expected to lead to a slight local re-organization 
of RNA secondary structure. The change of local structure would lead to an increased 
likelihood of complementary base pairing in the region. Current understanding is that 
increased complementary base pairing can physiologically prolong the half-life and amount 
of persisting mRNA. Although prediction of secondary structure is not necessarily a true 
delineation of intracellular secondary structures, we could demonstrate increased 
expression of FII mRNA in transfected cells as well as slightly increased FII protein levels 
in carriers of FII c.1824C>T. Increased FII levels are an established risk factor for VTE, 
through several mechanisms. Protein expression and concentrations were comparable to the 
levels seen in FII c.20210G>A . But the increased FII levels seem to exert the 
prothrombotic effect on the variants by two distinct mechanisms. Increased FII was 
associated with accelerated and increased thrombin generation in FII c.20210G>A , as well 
as shortened time to peak turbidity and clotting. The hypercoagulable profile was indicative 
of a mechanism where the elevated FII levels were associated with faster clotting and 
increased overall thrombin generation and peak thrombin concentration. In contrast, in FII 
c.1824C>T carriers, the increased FII levels were accompanied by an increased fibrin 
generation (OCP) and densely packed fibrin clots, as indicated by increased maximum 
turbidity 141 and visualized by SEM. We could also demonstrate hypofibrinolysis by 
decreased OFP and prolonged CLT in carriers of FII c.1824C>T. As described in the 
background, increased FII levels have been robustly associated with the formation of denser 
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fibrin clots with thin and highly branched fibers 170, which are in turn associated with 
resistance to fibrinolysis. The phenotypes have been associated with an increased VTE risk 
and identified in patients with acute ischemic and hemorrhagic stroke. In light of this, it is 
very interesting that in our investigation of effect allele frequency, the frequency of FII 
c.1824C>T was significantly increased in patients with both venous thromboembolism and 
cerebrovascular insult. Meanwhile, FVL and FII c.20210G>A  frequencies were only 
increased in VTE, consistent with the fact that they have only been robustly associated with 
venous thrombotic risk. Our findings suggest the possibility that FII c.1824C>T could be a 
risk factor for CVI and VTE through similar prothrombotic mechanism of action in both 
conditions. 
4.4.1 Methodological considerations of study III 
 
The key limitation of study III was the surprising extent of clinical samples that were 
collected in suboptimal preanalytical conditions. We had not anticipated that 49% of 
plasma samples would have been collected while patients were still receiving anticoagulant 
medication (>80% of patients with history of VTE). Nor did we expect that 50% of patients 
with history of VTE would be sampled within three weeks of the thrombotic event or that 
80% of patients in the FH group would be pregnant at sampling. The groups with different 
clinical indication for thrombophilia testing varied greatly regarding frequency of current 
anticoagulant medication 171-173, pregnancy 174, recent VTE 128 and general acute pathology, 
all transient factors that can influence OHP and ETP results. In short, the FH group 
consisted mainly of females with family history of VTE that were not treated with 
anticoagulant medication while the VTE groups, included a large portion of patients 
receiving anticoagulant medication for a recent thrombotic event.  
It seems probable that the low prevalence of hypercoagulable profiles would have been 
higher if they had been tested without anticoagulant medication, since it has been 
demonstrated that both thrombin generation and fibrin aggregation are decreased by 
anticoagulant treatment 171, 172, fibrinolysis has been demonstrated to be slightly increased 
in dabigatran treatment (OFP) 172. Conversely, it can be supposed that the wide range of 
hyper- and hypocoagulable GHA profiles reflected that the patients sampled for 
thrombophilia investigation while on anticoagulants were in different stages of treatment. It 
also seems possible that a second explanation for the heterogenous dispersion of 
coagulation profiles was the high prevalence of patients that were sampled shortly after 
suffering an acute VTE.   
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The overlap between positive results by the GHA and the conventional thrombophilia panel 
was relatively small, given that studies have verified correlations between these two. It 
seems probable that the transient interference of anticoagulant medication resulted in 
decreased GHA profiles in those patients with verifiable thrombophilia. Unfortunately, 
there were not enough samples without anticoagulants to reliably calculate the sensitivity or 
specificity of the global hemostatic assays to detect verified conventional thrombophilias.  
The converse relation, of transient hypercoagulability caused by pregnancy, is a probable 
explanation for the relatively frequent hypercoagulable result in the FH group and in 
patients without verified conventional thrombophilia. It is noteworthy that so many 
interfering factors were present in this descriptive study that was conducted solely in 
samples that have been used for clinical decision making. 
4.4.2 Methodological considerations in study IV 
The major limitation of study IV was the small number of FII c.1824C>T and c.20210G>A 
carriers recruited for the phenotype characterization. This was due to the low frequency of 
FII c.1824C>T in thrombotic patients, and the fact that in order to attain interpretable 
experiment results, we required investigated carriers to be completely without anticoagulant 
therapy. The small sample size may be the cause of some trends not achieving significant 
difference. The issue of insufficient power will be mitigated by the impending confirmation 
study in the KUL thrombophilia cohort. Another limitation which cannot be dismissed, 
considering that thrombosis is a multifactorial disorder, is the possible effect of unattributed 
confounding risk factors. Future studies addressing these limitations will contribute to the 
impact of the findings of this study. 
Despite small number of cases, western blot confirmed that FII c.1824C>T leads to a 
slightly increased concentration of prothrombin in carriers, although we did not detect an 
increase of FII activity. Poor correlation between prothrombin activity and concentration 
has also been demonstrated in carriers of FII c.202010G>A 175 and is likely explained by 
dysfunctional variants of prothrombin and in-vivo modulators of prothrombin activation 
and thrombin function. Coagulation times were not decreased in either of the FII variants, 
which is expected, since the maximal initial thrombin generation rate is attained in normal 
plasma concentrations of prothrombin. 
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4.4.3 Methodological considerations in study V 
The comparison of TiC and F5+F2+clinical factors revealed a discrete but statistically 
significant increase of AUC in favor of TiC. However, notwithstanding the significance of 
the ROC AUC differences, the clinical significance is uncertain. It seems improbable that a 
0.05 increase in AUCs to 0.7 could be translated into clinical value. Perhaps related  to this 
concern, a cost-effectiveness analysis has been published 176. The analysis was based on 
two case-control studies, since there are to date no prospective studies evaluating the effect 
of TiC as an intervention with VTE as the outcome.  
We need to acknowledge that the study was not powered to determine effect allele 
frequencies in the Swedish population, nor were the study participants a representative 
sample of the Swedish population. The frequencies of risk alleles were not a primary 
endpoint of this study, and were, as such, only presented for increased comprehensibility of 
the ROC results. 
The use of ROC in a non-prospective study should be commented. It is frequent in genetic 
diagnostic accuracy studies to calculate discriminatory ability by ROC and sensitivity/ 
specificity using thrombotic occurrences in patient history as though samples were 
prospectively collected. In the ROCs of study V, the different cutoffs represent number of 
variants for the evaluated GRS, with weights as per the TiC risk coefficients (Table 3).  
4.5 STUDY MODEL 
The approach that we used to collect study samples via the clinical chemistry laboratory is a 
compelling model to efficiently power a study. Considerable data can be obtained from 
laboratory information systems and analysis of left-over plasma without additional 
collection of research samples. However, it is important to be aware of the weaknesses of 
this method.  
The model is very sensitive to confounders, since these cannot be effectively managed in 
the inclusion process. A possible way to increase the specificity of inclusions is to form 
close collaborations with clinicians. If inclusions are done prospectively, there is an 
opportunity to gather prospectively collected data (eg. Wells Score). This necessitates a 
strict adhesion to GCP with detailed protocols and comprehensive start up meetings.  
A juxtaposed risk, which is present if patients are invited by letter is that extensive 
exclusions based on only information in the consent form could lead to a risk of small study 
samples. A strategy to prevent this could be to store samples from all consenting patients 
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and save exclusions to a later time-point. Continuous invitations, inclusion assessments and 
bio-banking are also laborious to perform in parallel with routine operations. Finally, if left-
over plasma samples are used, there is an appreciable risk of low sample volumes which the 
necessitates strict prioritizing of investigations in the samples.  
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5 CLINICAL IMPLICATIONS & FUTURE PERSPECTIVES 
5.1.1 Optimizing the use of D-dimer 
D-dimer is the only biomarker in routine clinical use for VTE, and the low specificity 
represents a significant problem. Increasing the effectiveness of the diagnostic process 
would be a clinical and economic breakthrough, especially considering the global disease 
burden of patients suffering from VTE. Study I added to the significant efforts of recent 
years that support age-adjusted cutoffs for D-dimer in DVT and PE. Our evaluation 
demonstrated that an adjusted cutoff resulted in a significant reduction in false positive 
results without decreased sensitivity, which reflects avoidable health risk, prolonged 
emergency department wait times and cost of imaging techniques without any compromise 
of clinical safety. We demonstrated that the unwarranted imaging to rule out VTE could be 
avoided in >5% of all patients with suspected disease, while in elderly patients as many as 
20% could avoid unnecessary imaging.  
The advantages of age adjusted D-dimer cutoffs are not uncontroversial 177 and the concept 
has also been challenged in a few recent studies These studies have shown an equal 
improvement of specificity and proportion of tests with negative results between age 
adjusted cutoffs vs. general increase of cutoffs in a low risk population with a 
corresponding low prevalence of VTE at 6.6 % 57 and 7.8 % 56, 58 for the studies 
respectively. Our investigation of ROC curves demonstrated that the sensitivity of the D-
dimer assays is rather resistant to changes of the cutoff if the cutoff is kept below 1 mg/L 
FEU, displayed in the cumulative data analysis curves (Figure 13). We interpret the 
findings of the mentioned studies as a symptom of this observation. In a population of low 
clinical probability, it is not surprising that the cutoff can be increased within this comfort 
zone without affecting sensitivity if the study population is not large enough. Since all 
utilization of D-dimer rests on the foundation of a reliably high sensitivity, a decrease of the 
robustness of the sensitivity could have negative consequences which would not be 
apparent before such an increase would be tested in a large prospective study. 
Instead the opposite course of action could be pertinent, i.e. a further individualization of 
the D-dimer cut-offs. Using the Tina-quant D-Di we revealed that in patients < 50 years 
(n=346), sensitivity was 0.91 and specificity 0.82. This is considerably lower than the CLSI 
requirements for sensitivity of D-dimer and raises the question whether the general cutoff is 
set too high for patients younger than 50?  Regrettably, our study was not powered to 
determine a suitable cutoff for only patients < 50 years, but the issue was recently 
 56 
 
addressed in a study demonstrating that the lowest levels of sensitivity of D-dimer were 
found in female patients, unprovoked DVT, low thrombotic burden, and distal DVT 178.  A 
fixed D-dimer cutoff 0.25 mg/L FEU in patients < 60 was suggested. In our cohort, 
applying this cutoff to the D-Di Tina-quant would result in sensitivity 0.97 and specificity 
0.52, which is a comparable to the specificity at 0.50 mg/L FEU in 60–70-year-old patients. 
Increasing the effectivity of the VTE diagnostic process has potentially major beneficial 
clinical and economical effects on the management of VTE. Because of the close 
association between the research group and the Karolinska clinical chemistry laboratory, 
clinical implementation of our findings could be more easily accomplished. Age-adjusted 
D-dimer cutoffs were clinically applied in Stockholm in late 2017 and have since been 
introduced in many parts of Sweden. The aim was that the fewer false positive results 
would enable diagnosis to become faster, cheaper and possibly result in decreased health 
risks from intravenous contrast, radiation and unnecessary hospital admissions and short-
term anticoagulation. A descriptive follow-up study of the clinical outcome of the 
implementation is underway, in collaboration between the PhD student and the Department 
of Medicine at Karolinska Institutet. Preliminary data from a small-scale evaluation of the 
implementation in Region Västmanland, was presented at the annual meeting of clinical 
chemistry in 2019; suggesting safe implementation and decreased false positive results. 
5.1.2 Global hemostatic assays in the diagnosis of venous thromboembolism 
As previously stated, there is significant room for improvement of the biochemical 
diagnosis of venous thromboembolism. However, identifying an assay superior to D-dimer 
has proven to be a challenge. Although some data point to the potential usefulness of the 
global hemostatic assays, a lack of standardization has hampered progress. Moreover, the 
diagnostic accuracy of ETP and OHP for acute VTE had not been assessed. The results of 
our study were in line with recent clinical evaluations of other thrombin generation assays 
for acute VTE. Our results indicated that neither the ETP nor the OHP assay would be 
clinically useful additions as biomarkers for the diagnosis of acute VTE in the emergency 
department. The evaluation of Soluble Fibrin for acute VTE, demonstrated that the 
increased diagnostic specificity of Soluble Fibrin in comparison with D-dimer came at the 
generally unacceptable cost of a decreased sensitivity. The study further implied that OHP 
and ETP were sensitive to hypercoagulability possibly caused by acute phase effects and 
comorbidities that may well be unavoidable in outpatients at the emergency department.  
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During the course of this thesis, the samples have been used in additional evaluations of 
feasible biomarkers of VTE which have also struggled with improving the diagnostic trade-
off of sensitivity and specificity beyond D-dimer. These, still unpublished findings of other 
biomarkers of acute VTE seem to implicate that a limited specificity for thrombotic events 
leads to similar assay difficulties as in D-dimer, ETP and OHP, that is high false positive 
rates in acute VTE. Since fibrin deposition in tissues in the absence of acute thrombotic 
events are common, it would perhaps be more fruitful to pursue highly specific biomarkers 
of VTE in the pathophysiological pathways initiating VTE. It is however operative to keep 
in mind that there are several triggering mechanisms and a possibility could be a 
partitioning between thrombosis and thromboembolism of various origin and the use of 
distinct biomarkers to diagnose acute VTE. 
5.1.3 Global hemostatic assays in the risk stratification of thrombophilia 
Study III was a cross-sectional descriptive study aimed to be a real-world pilot of the 
diagnostic landscape associated with expanding the current thrombophilia panel to include 
global hemostatic assays, which are emerging as general biomarkers of thrombotic risk. 
Knowledge of the diagnostic landscape can be used to strategically optimize 
implementation of the assays, not only from a clinical chemistry perspective.  
Addition of the ETP and OHP to the conventional thrombophilia panel led to an increased 
yield of objectively hypercoagulable results but did not evaluate how they should be 
interpreted in the thrombophilia investigation. The study accentuated that the ETP and OHP 
will only convey a snapshot of the patients’ coagulation profile. This makes proper 
sampling a very important issue if the GHA were to be clinically implemented for risk 
prediction of first or recurrent VTE.  
It is already known that the global hemostatic assays should be taken with the utmost 
attention to preanalytical details, but this study adds gravity to that knowledge. The 
possibility that ETP and OHP can risk false negative results in patients using anticoagulant 
medication and false positive results in patients suffering a recent VTE, may pose an 
obstacle to their correct clinical use as risk markers for recurrent VTE. The investigation of 
risk for first time VTE might be associated with less preanalytical pitfalls.  
In light of these examples, it is reasonable to assume that the global hemostatic assays will 
also risk improper sampling, whether it be due to lack of knowledge or with the expert 
knowledge to interpret results related to preanalytical sources of error. 
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The study highlighted difficulties of result interpretation in samples taken in suboptimal 
preanalytical conditions. Further prospective trials are needed to directly address if, how 
and when the global hemostatic assays could potentially be used as clinical biomarkers of 
thrombotic risk. Special attention should be directed to guiding proper clinical utilization of 
the assays, related to for example influence from anticoagulant medication, recent 
thrombotic events and acute phase reactions. 
A relevant parallel seems to be the correct utilization of the lupus anticoagulant assay, an 
assay that is commonly subject to pre-pre-analytical errors. For example, more than half of 
lupus anticoagulant testing in this cohort had been ordered in patients currently using 
anticoagulant medication. A considerable proportion of thrombophilia investigations was 
also initiated within a few weeks of diagnosis and treatment for acute VTE. The lacking 
adherence to pre-pre-analytical recommendations could well indicate an uncertainty as to 
when and how thrombophilia investigation and lupus anticoagulant are optimally tested. It 
may however instead reflect an informed practical strategy, aimed at shortening the 
turnaround times of investigation. Further research and clinical recommendations on the 
proper utilization of plasma based GHA related to anticoagulant medication and recent 
VTE would be useful.  
If the ETP and OHP were to be useful as part of investigation of the risk of a first or 
recurrent venous thrombosis, diagnostic sensitivity and clinical cut off values would most 
likely need to be further examined instead of using the 95th percentile normal ranges. 
Naturally, the determination of clinical cutoff values would need to be chosen with regard 
to the clinical intentions – whether a sensitivity could be reached, where the ETP or OHP 
could be used for initial screening of hypercoagulability and guidance of further 
thrombophilia investigation. 
Since the GHA parameters reflect somewhat different aspects of coagulation, an interesting 
prospect is that patients with different underlying hypercoagulability could possibly benefit 
from risk assessment by different GHA parameters. Future prospective studies comparing 
thrombin generation and fibrin aggregation assays would be needed to determine if one or 
both of these modalities would give the best clinical value.  
The highest proportion of hypercoagulable results in one parameter was seen in patients 
with a personal history of VTE combined with a family history of VTE, where 28% 
presented hypofibrinolytic profiles with decreased OFP. OFP may for example be the 
parameter most suited to detect thrombotic conditions where impaired fibrinolysis is an 
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important contributor to the hypercoagulable state, such as APS 146, 151, 179 or obstetrical 
patients 143. This study included only two APS patients without anticoagulation and hence 
cannot substantiate such a hypothesis, only hint at tendencies in different subgroups. It is 
worth noting that decreased fibrinolysis was at least as common as increased thrombin 
generation or fibrin aggregation in this study, and most common in patients with personal 
history of VTE in combination with family history of VTE. With this in mind, it would be 
interesting to further investigate clinical conditions related to decreased fibrinolysis. 
Likewise, an investigation of personalizing anticoagulant treatment according to 
hypercoagulability profiles would be of an interesting prospect and a are being investigated 
for at our laboratory adapted to the treatment of hemophilia patients . A possible future 
rationale for analyzing a combination of GHA could perhaps be guidance of individualized 
anticoagulation medication for patients with combined hypercoagulable risk factors but 
with predominantly hypofibrinolytic or hypercoagulable tendencies. Current evidence point 
to DOACs as less suitable for prophylaxis in APS patients 180, 181, in concurrence with the 
data suggesting that APS is partly related to impaired fibrinolysis 151.  
5.1.4 Prothrombotic variants as genetic markers of thrombophilia 
Addition of three additional prothrombotic SNPs in (Fibrinogen γ-chain (FGG), Factor XI 
(FXI) and the ABO blood group gene (ABO)), has been shown to improve the risk 
prediction for first time VTE and for recurrent VTE, with the risk increasing in proportion 
to the number of risk alleles.  
The clinical evaluation of additional prothrombotic polymorphisms in suspect 
thrombophilia, will be implemented into the clinical thrombophilia investigation panel 
within six months if the polymorphisms prove useful. 
Clinical genetic risk algorithms for VTE have the potential to improve the predictive ability 
of the classical genetic thrombophilia markers, but we could only demonstrate a slight 
improvement of ROC which is of uncertain clinical value. However, it should be 
acknowledged that a prospective advantage of TiC is that a CGRA is potentially easier to 
implement correctly, than an individual medical expert assessment, taking into account the 
relative importance of different clinical and genetic risk factors and possible interplays. In 
study III, some worrying indications of pre-pre-analytical difficulties were suggested, it 
might therefore be hypothesized that TiC could present a higher clinical value for the 
unaccustomed thrombophilia investigator. 
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5.1.5 Silent gene variants as attributors of thrombophilia heritability 
We explored a novel prothrombotic sSNP in the gene for prothrombin and found that it 
leads to increased expression and plasma levels of prothrombin, decreased fibrinolysis 
potential, prolonged clot lysis time and the formation of highly stabilized fibrin clots. This 
novel risk factor for thrombosis points to sSNPs as an uncharted component of unexplained 
thrombophilia heredity. We will continue to explore FII c.1824C>T, by further phenotype 
characterization and investigation of variant frequency in the KUL thrombophilia cohort. 
The confidence in FII c.1824C>T  as a prothrombotic SNP would be strengthened if it 
would be identified in GWAS. A recent meta-analysis did not identify FII c.1824C>T as a 
potential risk factor of VTE 182. It has since been elucidated that risk-stratification for 
venous thromboembolism should be treated as two distinct risks; that of first VTE and that 
of second VTE. FII c.1824C>T is only suggested as a risk factor of first VTE.  
An established weakness of GWAS is their low ability to identify relevant variants with an 
EAF <0.01 as well as common variants associated with mild effects. In addition, 
synonymous variants are disregarded in VTE GWAS. Given the evidence that corroborate 
the role of sSNPs in VTE pathophysiology, whole exome sequencing with 
acknowledgement of potential sSNPs would decidedly be preferable in future genetic 
explorations of thrombotic risk. 
5.1.6 Thrombophilia testing  
As discussed earlier, the future of thrombophilia testing is uncertain. Conventional 
thrombophilia investigation has not been shown to improve outcomes in tested patients. 
Indeed, it may be unsurprising that the analysis of two mild genetic risk factors together 
with a handful of very uncommon anticoagulant deficiencies does not give population-scale 
impact on outcomes and that isolated testing of APS is the main thrombophilias testing 
currently recommended by several experts. However, it seems backward to not further 
investigate the potentials of personalized health care for VTE, which is an important global 
cause of morbidity and mortality, just as we are emerging into the digitalized era. It seems 
more probable that we will be able to elucidate complex diseases such as VTE than ever 
before, as machine learning solutions may be required to interpret data from whole exome 
explorations, miRNA, SNP-SNP-interactions and other mechanisms still unknown to us.  
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6 CONCLUSIONS 
6.1 STUDY I  
A prospective single-center study indicating that age-adjusted D-dimer cutoffs can 
eliminate false positive results in more than 5% of all patients with suspected VTE.           
In elderly patients with suspected VTE the decrease in false positive results could even 
affect as many as 20% of patients. Results were valid for four different reagents. 
6.2 STUDY II 
A cross-sectional diagnostic study where the OHP and Innovance® ETP assays did not 
improve the diagnosis of acute VTE in emergency department outpatient.  
The study suggested that many patients are in a hypercoagulable state when contacting the 
emergency department for suspected VTE, due in part to an increased fibrinogen levels.  
6.3 STUDY III 
A cross-sectional descriptive study indicating that at least a slightly increased proportion of 
patients could be given graduated risk assessments based on the analysis of thrombin 
generation and fibrin aggregation.  
The study highlighted some difficulties of result interpretation in samples taken in 
suboptimal preanalytical conditions, present in the samples that had been clinically used for 
laboratory investigation of each patient.  
6.4 STUDY IV 
A translational study, elucidating the functional effects of a newly identified synonymous 
polymorphism. The study could corroborate the FII c.1824C>T variant as a feasible 
contributor to thrombotic risk by functional explorations of coding DNA, via mRNA and 
proteins to a comprehensive overview of the hemostatic profiles in carriers of the sSNP.   
6.5 STUDY V 
A cross-sectional diagnostic study indicating that a clinical-genetic algorithm developed in 
Spain had similar discriminative ability in a nonpregnant Swedish population sample, 
despite significant differences in the allelic frequencies of included genetic variants.  
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